<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://thorax.bmj.com">
<title>Thorax Online First</title>
<link>http://thorax.bmj.com</link>
<description>Thorax RSS Feed -- Online First</description>
<prism:publicationName>Thorax</prism:publicationName>
<prism:issn>0040-6376</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202052v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201869v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202014v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202054v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201765v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201825v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201262v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201420v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200699v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201581v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201923v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200953v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201991v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200835v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201445v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201657v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201987v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201484v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201140v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200253v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201758v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201679v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201028v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201454v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201868v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201309v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200863v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201720v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200690v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201739v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200391v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201096v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201363v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201827v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201838v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201830v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201321v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201655v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200266v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201829v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201828v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201092v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201088v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200018v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201469v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201001v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200160v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201549v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201524v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201683v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201726v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201703v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201384v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201193v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201081v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201512v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200832v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201064v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201579v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201596v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200949v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200279v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201666v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201308v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201582v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201249v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200651v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201409v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200874v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201436v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201607v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201669v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201586v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200424v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200864v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201422v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201587v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201176v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200829v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201453v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201279v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201168v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200405v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200912v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201383v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201418v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201438v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201439v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201437v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200606v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200859v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201372v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201078v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200508v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201329v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201097v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201059v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201327v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201267v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201149v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201328v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201043v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200980v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200206v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200876v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200822v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200766v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200762v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200695v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200657v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200870v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200662v2?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200515v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200467v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200088v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thx.2010.142653v1?rss=1" />
  <rdf:li rdf:resource="http://thorax.bmj.com/cgi/content/short/thx.2009.133496v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://thorax.bmj.com/site/homepage/Thorax_95x60.gif" />
</channel>
<image rdf:about="http://thorax.bmj.com/site/homepage/Thorax_95x60.gif">
<title>Thorax</title>
<url>http://thorax.bmj.com/site/homepage/Thorax_95x60.gif</url>
<link>http://thorax.bmj.com</link>
</image>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202052v1?rss=1">
<title><![CDATA[Host genotype-specific therapies for tuberculosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202052v1?rss=1</link>
<description><![CDATA[<p>This paper suggests that therapies for tuberculosis (TB) will, in the future, be tuned specifically to the patient's genotype. Using zebra fish and human models, Tobin <I>et al</I> demonstrated that susceptibility to TB can be caused by both reduced and increased inflammatory activity, which in turn is governed by the patient's genotype. The increased inflammatory pathway begins with increased leukotriene A4 hydrolase (LTA4H) activity, which leads to increased production of a proinflammatory eicosanoid (LBT4) and tumour necrosis factor. The decreased inflammatory pathway begins with reduced LTA4H activity resulting in increased anti-inflammatory activity and increased production of lipoxins. Both mechanisms cause lysis of macrophages.</p><p>These findings suggests that by identifying whether a patient infected with TB is in a high or reduced inflammatory state, as dictated by their LTA4H genotype and the detrimental effects of each extreme countered, patient morbidity and mortality would be improved. Blindly used &lsquo;scatter-gun&rsquo; therapies may be either...]]></description>
<dc:creator><![CDATA[Devlin, J.]]></dc:creator>
<dc:date>2012-05-12T02:01:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-202052</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-202052</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Host genotype-specific therapies for tuberculosis]]></dc:title>
<prism:publicationDate>2012-05-12</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201869v1?rss=1">
<title><![CDATA[Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201869v1?rss=1</link>
<description><![CDATA[<p>Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.</p>]]></description>
<dc:creator><![CDATA[Sweeney, J., Brightling, C. E., Menzies-Gow, A., Niven, R., Patterson, C. C., Heaney, L. G., on behalf of the British Thoracic Society Difficult Asthma Network]]></dc:creator>
<dc:date>2012-05-11T02:01:10-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201869</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201869</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Asthma]]></dc:subject>
<dc:title><![CDATA[Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry]]></dc:title>
<prism:publicationDate>2012-05-11</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202014v1?rss=1">
<title><![CDATA[Safety of long-acting {beta}-agonists in asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202014v1?rss=1</link>
<description><![CDATA[<p>The study by Wolfe <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> certainly does not support our claim that serious asthma exacerbations are more frequent in patients receiving formoterol 24&nbsp;&mu;g twice daily than in those receiving 12&nbsp;&mu;g twice daily, or placebo.<cross-ref type="bib" refid="b2">2</cross-ref> Actually, this statement should have been based on the review by Mann <I>et al</I>,<cross-ref type="bib" refid="b3">3</cross-ref> that assessed data from three prospective, randomised, placebo-controlled and double-blind studies of formoterol at different dosages submitted to the US Food and Drug Administration. The authors concluded that more patients treated regularly with formoterol 24&nbsp;&mu;g twice daily had serious asthma exacerbations than did patients who had been treated with formoterol 12&nbsp;&mu;g twice daily, or placebo (4.5% vs 2.0%, vs 0.4%, respectively). In any case, evidence from controlled studies suggests that the use of long-acting &beta;-agonists added to inhaled corticosteroids is safe and effective for the treatment of asthma.</p><p><fn><no>Competing interests</no><p>None.</p></fn></p><p><fn><no>Provenance and peer review</no><p>Not commissioned; internally peer...]]></description>
<dc:creator><![CDATA[Rodrigo, G. J., Castro-Rodriguez, J. A.]]></dc:creator>
<dc:date>2012-05-10T02:01:23-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-202014</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-202014</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Safety of long-acting {beta}-agonists in asthma]]></dc:title>
<prism:publicationDate>2012-05-10</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202054v1?rss=1">
<title><![CDATA[Effects of school closure on incidence of pandemic influenza in Alberta, Canada]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-202054v1?rss=1</link>
<description><![CDATA[<p>This study uses data from the influenza pandemic in Alberta, Canada in 2009 to investigate whether incidence and transmission are affected by weather changes and school closure.</p><p>During a 9-month period 35, 510 influenza tests were performed in Alberta, of which 19% tested positive for pandemic H1N1 (pH1N1). Using mathematical transmission modelling, the study compared the confirmed cases of pH1N1 with weather patterns and the school calendar.</p><p>The results suggested that the end of the school term had a significant impact in reducing the first &lsquo;wave&rsquo; of the pandemic; modelling showed transmission rates dropped in school children by more than 50% following school closure. A second wave of pH1N1 occurred shortly after school re-opening. Transmission was also affected by climate changes such as a low temperature, which correlated with increased transmission.</p><p>The study is limited in that it only takes into account cases of influenza that were confirmed virologically, meaning that data is...]]></description>
<dc:creator><![CDATA[Downie, B.]]></dc:creator>
<dc:date>2012-05-10T02:01:23-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-202054</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-202054</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Effects of school closure on incidence of pandemic influenza in Alberta, Canada]]></dc:title>
<prism:publicationDate>2012-05-10</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201765v1?rss=1">
<title><![CDATA[Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201765v1?rss=1</link>
<description><![CDATA[<p>Skeletal muscle dysfunction is a prevalent and clinically important systemic manifestation of chronic obstructive pulmonary disease (COPD) that predicts morbidity and mortality. Skeletal muscle retains its plasticity in response to anabolic stimuli such as exercise in COPD and is therefore a promising target for novel pharmacological therapies aimed at reducing disability and healthcare utilisation and improving mortality. In this article, we outline the steps the academic and pharmaceutical communities need to undertake for such therapeutic advances to be realised.</p>]]></description>
<dc:creator><![CDATA[Steiner, M. C., Roubenoff, R., Tal-Singer, R., Polkey, M. I.]]></dc:creator>
<dc:date>2012-05-05T02:03:12-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201765</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201765</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review]]></dc:title>
<prism:publicationDate>2012-05-05</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201825v1?rss=1">
<title><![CDATA[The diagnosis of asthma, a clinical syndrome]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201825v1?rss=1</link>
<description><![CDATA[<p>Clinical experience and now genetic data indicate that asthma is a heterogeneous clinical syndrome&mdash;clinical cases emerge, proceed and respond to treatments in different ways. Currently the diagnosis of asthma (as enunciated in national guidelines) is based on incisive clinical methods, supported by lung function testing that substantiates labile or reversible bronchial airflow obstruction. But this approach alone is insufficient to address the diagnostic and therapeutic challenges presented by asthma's heterogeneity. This article contends that bronchial pathology (with molecular and morphologic analysis) should be adopted into the mainstream clinical practice of asthma so as to clarify the nature of the bronchial disorder in compliant patients not settling securely on moderate-dose inhaled corticosteroid. This would allow a differentiated approach to appropriate therapeutics&mdash;those already available and those yet to be developed.</p>]]></description>
<dc:creator><![CDATA[Hopkin, J. M.]]></dc:creator>
<dc:date>2012-05-05T02:03:12-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201825</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201825</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[The diagnosis of asthma, a clinical syndrome]]></dc:title>
<prism:publicationDate>2012-05-05</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201262v1?rss=1">
<title><![CDATA[Genome-wide association study to identify genetic determinants of severe asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201262v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The genetic basis for developing asthma has been extensively studied. However, association studies to date have mostly focused on mild to moderate disease and genetic risk factors for severe asthma remain unclear.</p></sec><sec><st>Objective</st><p>To identify common genetic variants affecting susceptibility to severe asthma.</p></sec><sec><st>Methods</st><p>A genome-wide association study was undertaken in 933 European ancestry individuals with severe asthma based on Global Initiative for Asthma (GINA) criteria 3 or above and 3346 clean controls. After standard quality control measures, the association of 480 889 genotyped single nucleotide polymorphisms (SNPs) was tested. To improve the resolution of the association signals identified, non-genotyped SNPs were imputed in these regions using a dense reference panel of SNP genotypes from the 1000 Genomes Project. Then replication of SNPs of interest was undertaken in a further 231 cases and 1345 controls and a meta-analysis was performed to combine the results across studies.</p></sec><sec><st>Results</st><p>An association was confirmed in subjects with severe asthma of loci previously identified for association with mild to moderate asthma. The strongest evidence was seen for the <I>ORMDL3</I>/<I>GSDMB</I> locus on chromosome 17q12-21 (rs4794820, p=1.03<FONT FACE="arial,helvetica">x</FONT>10<sup>(&ndash;8)</sup> following meta-analysis) meeting genome-wide significance. Strong evidence was also found for the <I>IL1RL1</I>/<I>IL18R1</I> locus on 2q12 (rs9807989, p=5.59<FONT FACE="arial,helvetica">x</FONT>10<sup>(&ndash;8)</sup> following meta-analysis) just below this threshold. No novel loci for susceptibility to severe asthma met strict criteria for genome-wide significance.</p></sec><sec><st>Conclusions</st><p>The largest genome-wide association study of severe asthma to date was carried out and strong evidence found for the association of two previously identified asthma susceptibility loci in patients with severe disease. A number of novel regions with suggestive evidence were also identified warranting further study.</p></sec>]]></description>
<dc:creator><![CDATA[Wan, Y. I., Shrine, N. R. G., Soler Artigas, M., Wain, L. V., Blakey, J. D., Moffatt, M. F., Bush, A., Chung, K. F., Cookson, W. O. C. M., Strachan, D. P., Heaney, L., Al-Momani, B. A. H., Mansur, A. H., Manney, S., Thomson, N. C., Chaudhuri, R., Brightling, C. E., Bafadhel, M., Singapuri, A., Niven, R., Simpson, A., Holloway, J. W., Howarth, P. H., Hui, J., Musk, A. W., James, A. L., the Australian Asthma Genetics Consortium, Brown, M. A., Baltic, S., Ferreira, M. A. R., Thompson, P. J., Tobin, M. D., Sayers, I., Hall, I. P.]]></dc:creator>
<dc:date>2012-05-05T02:03:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201262</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201262</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Asthma]]></dc:subject>
<dc:title><![CDATA[Genome-wide association study to identify genetic determinants of severe asthma]]></dc:title>
<prism:publicationDate>2012-05-05</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201420v1?rss=1">
<title><![CDATA[Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201420v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale and objectives</st><p>Impaired insulin sensitivity (ISx), increased visceral abdominal fat (VAF) and liver fat are all central components of the metabolic syndrome and characteristics of men with obstructive sleep apnoea (OSA). The reversibility of these observed changes with continuous positive airway pressure (CPAP) treatment in men with OSA has not been systematically studied in a randomised sham-controlled fashion.</p></sec><sec><st>Methods</st><p>65 men without diabetes who were CPAP na&iuml;ve and had moderate to severe OSA (age=49&plusmn;12&nbsp;years, apnoea hypopnoea index (AHI)=39.9&plusmn;17.7&nbsp;events/h, body mass index=31.3&plusmn;5.2&nbsp;kg/m<sup>2</sup>) were randomised to receive either real (n=34) or sham (n=31) CPAP for 12&nbsp;weeks. At 12&nbsp;weeks, all subjects received real CPAP for an additional 12&nbsp;weeks.</p></sec><sec><st>Measurements and main results</st><p>Main outcomes were the change at week 12 from baseline in VAF, ISx and liver fat. Other metabolic outcomes were changes in the disposition index, total fat, and blood leptin and adiponectin concentrations. The AHI was lower on CPAP compared with sham by 33&nbsp;events/h (95% CI&ndash;43.9 to &ndash;22.2, p&lt;0.0001) after 12&nbsp;weeks. There were no between-group differences at 12&nbsp;weeks in VAF (&ndash;13.0&nbsp;cm<sup>3</sup>, &ndash;42.4 to 16.2, p=0.37), ISx (&ndash;0.13 (min<sup>&ndash;1</sup>)(&mu;U/ml))<sup>&ndash;1</sup>, &ndash;0.40 to 0.14, p=0.33), liver fat (&ndash;0.5&nbsp;cm<sup>3</sup>, &ndash;3.8 to 2.7, p=0.74) or any other cardiometabolic parameter. At 24&nbsp;weeks, ISx (3.2<FONT FACE="arial,helvetica">x</FONT>10<sup>4</sup> (min<sup>&ndash;1</sup>)(&mu;U/ml))<sup>&ndash;1</sup>, 0.9<FONT FACE="arial,helvetica">x</FONT>10<sup>4</sup> to 6.0<FONT FACE="arial,helvetica">x</FONT>10<sup>4</sup>, p=0.009), but not VAF (&ndash;1.4&nbsp;cm<sup>3</sup>, &ndash;19.2 to 16.4, p=0.87) or liver fat (&ndash;0.2 Hounsfield units, &ndash;2.4 to 2.0, p=0.83) were improved compared with baseline in the whole study group.</p></sec><sec><st>Conclusion</st><p>Reducing visceral adiposity in men with OSA cannot be achieved with CPAP alone and is likely to require weight-loss interventions. Longer-term effects of CPAP on other cardiometabolic markers such as ISx require further investigation to fully examine time dependencies.</p></sec><sec><st>Trial Registration Number</st><p>ACTRN12608000301369.</p></sec>]]></description>
<dc:creator><![CDATA[Hoyos, C. M., Killick, R., Yee, B. J., Phillips, C. L., Grunstein, R. R., Liu, P. Y.]]></dc:creator>
<dc:date>2012-05-05T02:03:14-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201420</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201420</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health education, Obesity (public health)]]></dc:subject>
<dc:title><![CDATA[Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study]]></dc:title>
<prism:publicationDate>2012-05-05</prism:publicationDate>
<prism:section>Sleep disordered breathing</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200699v1?rss=1">
<title><![CDATA[Continuous measures of driving performance on an advanced office-based driving simulator can be used to predict simulator task failure in patients with obstructive sleep apnoea syndrome]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200699v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>Some patients with obstructive sleep apnoea syndrome are at higher risk of being involved in road traffic accidents. It has not been possible to identify this group from clinical and polysomnographic information or using simple simulators. We explore the possibility of identifying this group from variables generated in an advanced PC-based driving simulator.</p></sec><sec><st>Methods</st><p>All patients performed a 90&nbsp;km motorway driving simulation. Two events were programmed to trigger evasive actions, one subtle and an alert driver should not crash, while for the other, even a fully alert driver might crash. Simulator parameters including standard deviation of lane position (SDLP) and reaction times at the veer event (VeerRT) were recorded. There were three possible outcomes: &lsquo;fail&rsquo;, &lsquo;indeterminate&rsquo; and &lsquo;pass&rsquo;. An exploratory study identified the simulator parameters predicting a &lsquo;fail&rsquo; by regression analysis and this was then validated prospectively.</p></sec><sec><st>Results</st><p>72 patients were included in the exploratory phase and 133 patients in the validation phase. 65 (32%) patients completed the run without any incidents, 45 (22%) failed, 95 (46%) were indeterminate. Prediction models using SDLP and VeerRT could predict &lsquo;fails&rsquo; with a sensitivity of 82% and specificity of 96%. The models were subsequently confirmed in the validation phase.</p></sec><sec><st>Conclusions</st><p>Using continuously measured variables it has been possible to identify, with a high degree of accuracy, a subset of patients with obstructive sleep apnoea syndrome who fail a simulated driving test. This has the potential to identify at-risk drivers and improve the reliability of a clinician's decision-making.</p></sec>]]></description>
<dc:creator><![CDATA[Ghosh, D., Jamson, S. L., Baxter, P. D., Elliott, M. W.]]></dc:creator>
<dc:date>2012-05-05T02:03:13-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200699</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200699</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Continuous measures of driving performance on an advanced office-based driving simulator can be used to predict simulator task failure in patients with obstructive sleep apnoea syndrome]]></dc:title>
<prism:publicationDate>2012-05-05</prism:publicationDate>
<prism:section>Sleep disordered breathing</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201581v1?rss=1">
<title><![CDATA[The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201581v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>Health status is impaired in patients with interstitial lung disease (ILD). There is a paucity of tools that assess health status in ILD. The objective of this study was to develop and validate the King's Brief Interstitial Lung Disease questionnaire (K-BILD), a new health status measure for patients with ILD.</p></sec><sec><st>Methods</st><p>Patients with ILD were recruited from outpatient clinics. The development of the questionnaire consisted of three phases: item generation; item reduction, allocation to domains by factor analysis, Rasch analysis to create unidimensional scales and validation; and repeatability testing.</p></sec><sec><st>Results</st><p>173 patients with ILD (49 with idiopathic pulmonary fibrosis) completed a preliminary 71-item questionnaire. 56 items were removed due to redundancy, low factor loadings or poor fit to the Rasch model. The final version of the K-BILD questionnaire consisted of 15 items and three domains (breathlessness and activities, chest symptoms and psychological). Internal consistency assessed with Cronbach's &alpha; coefficient was 0.94 for the K-BILD total score. Concurrent validity of the K-BILD questionnaire was high compared with St George's Respiratory Questionnaire (r=0.90) and moderate with lung function (vital capacity, r=0.50). The K-BILD questionnaire was repeatable over 2&nbsp;weeks (n=44), with intraclass correlation coefficients for domains and total score 0.86&ndash;0.94. The K-BILD construct validity for patients with idiopathic pulmonary fibrosis was similar to that of other ILDs.</p></sec><sec><st>Conclusion</st><p>The K-BILD questionnaire is a brief, valid, self-completed health status measure for ILD. It could be used in the clinic to assess ILD from the patients' perspective.</p></sec>]]></description>
<dc:creator><![CDATA[Patel, A. S., Siegert, R. J., Brignall, K., Gordon, P., Steer, S., Desai, S. R., Maher, T. M., Renzoni, E. A., Wells, A. U., Higginson, I. J., Birring, S. S.]]></dc:creator>
<dc:date>2012-05-03T02:04:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201581</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201581</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Interstitial lung disease]]></dc:subject>
<dc:title><![CDATA[The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire]]></dc:title>
<prism:publicationDate>2012-05-03</prism:publicationDate>
<prism:section>Interstitial lung disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201923v1?rss=1">
<title><![CDATA[Mesenchymal stem cells]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201923v1?rss=1</link>
<description><![CDATA[<p>Mesenchymal Stem cells (MSCs) are stromal cells that can be readily harvested from adult bone marrow and adipose tissue, but also umbilical cords. With respect to respiratory disease, the therapeutic potential of these cells lies in their paracrine effects which underlie their ability to enhance tissue regeneration and modulate immune responses. MSCs have been shown to be effective in a range of murine models of respiratory disease, and there are currently five clinical trials involving the administration of MSCs for respiratory diseases, including COPD and emphysema. This paper summarises the features of MSCs.</p>]]></description>
<dc:creator><![CDATA[Rankin, S.]]></dc:creator>
<dc:date>2012-05-03T02:04:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201923</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201923</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mesenchymal stem cells]]></dc:title>
<prism:publicationDate>2012-05-03</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200953v1?rss=1">
<title><![CDATA[Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200953v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Forced expiratory volume in 1 s as a percentage of predicted (%FEV<SUB>1</SUB>) is a key outcome in cystic fibrosis (CF) and other lung diseases. As people with CF survive for longer periods, new methods are required to understand the way %FEV<SUB>1</SUB> changes over time. An up to date approach for longitudinal modelling of %FEV<SUB>1</SUB> is presented and applied to a unique CF dataset to demonstrate its utility at the clinical and population level.</p></sec><sec><st>Methods and findings</st><p>The Danish CF register contains 70 448 %FEV<SUB>1</SUB> measures on 479 patients seen monthly between 1969 and 2010. The variability in the data is partitioned into three components (between patient, within patient and measurement error) using the empirical variogram. Then a linear mixed effects model is developed to explore factors influencing %FEV<SUB>1</SUB> in this population. Lung function measures are correlated for over 15&nbsp;years. A baseline %FEV<SUB>1</SUB> value explains 63% of the variability in %FEV<SUB>1</SUB> at 1&nbsp;year, 40% at 3&nbsp;years, and about 30% at 5&nbsp;years. The model output smooths out the short-term variability in %FEV<SUB>1</SUB> (SD 6.3%), aiding clinical interpretation of changes in %FEV<SUB>1</SUB>. At the population level significant effects of birth cohort, pancreatic status and <I>Pseudomonas aeruginosa</I> infection status on %FEV<SUB>1</SUB> are shown over time.</p></sec><sec><st>Conclusions</st><p>This approach provides a more realistic estimate of the %FEV<SUB>1</SUB> trajectory of people with chronic lung disease by acknowledging the imprecision in individual measurements and the correlation structure of repeated measurements on the same individual over time. This method has applications for clinicians in assessing prognosis and the need for treatment intensification, and for use in clinical trials.</p></sec>]]></description>
<dc:creator><![CDATA[Taylor-Robinson, D., Whitehead, M., Diderichsen, F., Olesen, H. V., Pressler, T., Smyth, R. L., Diggle, P.]]></dc:creator>
<dc:date>2012-05-03T02:04:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200953</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200953</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Unlocked, Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study]]></dc:title>
<prism:publicationDate>2012-05-03</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201991v1?rss=1">
<title><![CDATA[Safety of long-acting {beta}2-agonists in asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201991v1?rss=1</link>
<description><![CDATA[<p>In their review on the safety of long-acting &beta;2-agonists in asthma, Rodrigo <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> report that severe asthma-related complications were more frequent in patients receiving formoterol 24&nbsp;&mu;g twice daily (0.9%) than in those receiving formoterol 12&nbsp;&mu;g twice daily (0.4%) or placebo (0.2%) in a multicentre randomised trial.<cross-ref type="bib" refid="b2">2</cross-ref> The original study reports different percentages of asthma-related complications in the treatment groups (<cross-ref type="tbl" refid="tbl1">table 1</cross-ref>), and both serious asthma exacerbations and a combined outcome including serious asthma exacerbations, asthma-related discontinuations and emergency visits for asthma did not show statistically significant differences between the treatment groups.<cross-ref type="bib" refid="b2">2</cross-ref> Consequently, the statement by Rodrigo <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> that higher doses of formoterol are associated with an increase in serious asthma exacerbations is disputable. Concerns about the safety of long-acting &beta;2-agonists therapy are a matter of ongoing discussion, and a recently promoted FDA study<cross-ref type="bib" refid="b3">3</cross-ref> may hopefully clarify...]]></description>
<dc:creator><![CDATA[de Benedictis, F. M., Carloni, I.]]></dc:creator>
<dc:date>2012-05-01T02:02:03-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201991</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201991</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Safety of long-acting {beta}2-agonists in asthma]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200835v1?rss=1">
<title><![CDATA[Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200835v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Exposure to cigarette smoke (CS) is associated with increased risk of pneumococcal infection. The mechanism for this association is unknown. We recently reported that the particulate matter from urban air simulates platelet-activating factor receptor (PAFR)-dependent adhesion of pneumococci to airway cells. We therefore sought to determine whether CS stimulates pneumococcal adhesion to airway cells.</p></sec><sec><st>Methods</st><p>Human alveolar (A549), bronchial (BEAS2-B), and primary bronchial epithelial cells (HBEpC) were exposed to CS extract (CSE), and adhesion of <I>Streptococcus pneumoniae</I> determined. The role of PAFR in mediating adhesion was determined using a blocker (CV-3988). PAFR transcript level was assessed by quantitative real-time PCR, and PAFR expression by flow cytometry. Lung PAFR transcript level was assessed in mice exposed to CS, and bronchial epithelial PAFR expression assessed in active-smokers by immunostaining.</p></sec><sec><st>Results</st><p>In A549 cells, CSE 1% increased pneumococcal adhesion (p&lt;0.05 vs control), PAFR transcript level (p&lt;0.01), and PAFR expression (p&lt;0.01). Pneumococcal adhesion to A549 cells was attenuated by CV-3988 (p&lt;0.001). CSE 1% stimulated pneumococcal adhesion to BEAS2-B cells and HBEpC (p&lt;0.01 vs control). CSE 1% increased PAFR expression in BEAS2-B (p&lt;0.01), and in HBEpC (p&lt;0.05). Lung PAFR transcript level was increased in mice exposed to CS in vivo (p&lt;0.05 vs room air). Active smokers (n=16) had an increased percentage of bronchial epithelium with PAFR-positive cells (p&lt;0.05 vs never smokers, n=11).</p></sec><sec><st>Conclusion</st><p>CSE stimulates PAFR-dependent pneumococcal adhesion to lower airway epithelial cells. We found evidence that CS increases bronchial PAFR in vivo.</p></sec>]]></description>
<dc:creator><![CDATA[Grigg, J., Walters, H., Sohal, S. S., Wood-Baker, R., Reid, D. W., Xu, C.-B., Edvinsson, L., Morissette, M. C., Stampfli, M. R., Kirwan, M., Koh, L., Suri, R., Mushtaq, N.]]></dc:creator>
<dc:date>2012-05-01T02:02:03-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200835</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200835</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells]]></dc:title>
<prism:publicationDate>2012-05-01</prism:publicationDate>
<prism:section>Respiratory infection</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201445v1?rss=1">
<title><![CDATA[Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201445v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>Criteria for a clinically significant bronchodilator response (BDR) are mainly based on studies in patients with obstructive lung diseases. Little is known about the BDR in healthy general populations, and even less about the worldwide patterns.</p></sec><sec><st>Methods</st><p>10 360 adults aged 40&nbsp;years and older from 14 countries in North America, Europe, Africa and Asia participated in the Burden of Obstructive Lung Disease study. Spirometry was used before and after an inhaled bronchodilator to determine the distribution of the BDR in population-based samples of healthy non-smokers and individuals with airflow obstruction.</p></sec><sec><st>Results</st><p>In 3922 healthy never smokers, the weighted pooled estimate of the 95th percentiles (95% CI) for bronchodilator response were 284&nbsp;ml (263 to 305) absolute change in forced expiratory volume in 1 s from baseline (FEV<SUB>1</SUB>); 12.0% (11.2% to 12.8%) change relative to initial value (%FEV<SUB>1i</SUB>); and 10.0% (9.5% to 10.5%) change relative to predicted value (%FEV<SUB>1p</SUB>). The corresponding mean changes in forced vital capacity (FVC) were 322&nbsp;ml (271 to 373) absolute change from baseline (FVC); 10.5% (8.9% to 12.0%) change relative to initial value (FVC<SUB>i</SUB>); and 9.2% (7.9% to 10.5%) change relative to predicted value (FVC<SUB>p</SUB>). The proportion who exceeded the above threshold values in the subgroup with spirometrically defined Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 and higher (FEV<SUB>1</SUB>/FVC &lt;0.7 and FEV<SUB>1</SUB>% predicted &lt;80%) were 11.1%, 30.8% and 12.9% respectively for the FEV<SUB>1</SUB>-based thresholds and 22.6%, 28.6% and 22.1% respectively for the FVC-based thresholds.</p></sec><sec><st>Conclusions</st><p>The results provide reference values for bronchodilator responses worldwide that confirm guideline estimates for a clinically significant level of BDR in bronchodilator testing.</p></sec>]]></description>
<dc:creator><![CDATA[Tan, W. C., Vollmer, W. M., Lamprecht, B., Mannino, D. M., Jithoo, A., Nizankowska-Mogilnicka, E., Mejza, F., Gislason, T., Burney, P. G. J., Buist, A. S., for the BOLD Collaborative Research Group]]></dc:creator>
<dc:date>2012-04-29T02:01:09-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201445</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201445</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Airway biology, Lung function, Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study]]></dc:title>
<prism:publicationDate>2012-04-29</prism:publicationDate>
<prism:section>Respiratory epidemiology</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201657v1?rss=1">
<title><![CDATA[Stability of inflammatory phenotypes in asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201657v1?rss=1</link>
<description><![CDATA[<p>While asthma has long been recognised as a heterogeneous disease, recent interest has concentrated on the identification of phenotypes based on the pattern of inflammation in the airways. The application of induced sputum as a non-invasive &lsquo;inflammometer&rsquo; has facilitated this process, resulting in the recognition of apparently distinct &lsquo;eosinophilic&rsquo; and &lsquo;non-eosinophilic&rsquo; phenotypes. The characterisation of patients in this way appears attractive since the response to treatment, particularly with inhaled corticosteroids, has been shown to differ according to the pattern and extent of inflammation. This has contributed to the concept of a &lsquo;holy grail&rsquo; of individualised therapy based on phenotypic expression and a flurry of studies aiming to further explain and refine the phenotypic diversity seen in both adults and children with asthma. A number of questions remain, however, and one important one raised by Fleming <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> is whether there are differences in the nature and significance of...]]></description>
<dc:creator><![CDATA[Green, R. H., Pavord, I.]]></dc:creator>
<dc:date>2012-04-27T02:02:42-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201657</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201657</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Inflammation, Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[Stability of inflammatory phenotypes in asthma]]></dc:title>
<prism:publicationDate>2012-04-27</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201987v1?rss=1">
<title><![CDATA[Acronyms, pneumothoraces and the impact of international health on the NHS]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201987v1?rss=1</link>
<description><![CDATA[<p>I read the latest Issue of <I>Thorax</I> with amusement and frustration.</p><p>I could not resist your challenge in your Editorial, &lsquo;Pre-drainage tension&rsquo;, triggered by letters from Drs Simpson and Leigh Smith<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> to make a ridiculous acronym.<cross-ref type="bib" refid="b3">3</cross-ref></p><p>My understanding of pneumothorax was that it is due to a loss of the negative intrapleural pressure that overcomes the elastic recoil of the pulmonary tissues. Once this vacuum is lost then air is free to enter the lungs or intrapleural space with impunity. The actual amounts will vary according to many factors, including the strength of elastic recoil of pulmonary tissues, exact sites of leak and depth of inspiration. Perhaps we need an engineer to explain this?</p><p>However, on first reading of the letters I was concerned that all texts on the issue including life support and trauma courses would have to be REPRINTED (Rapidly Expanding Pneumothorax Requiring Immediate...]]></description>
<dc:creator><![CDATA[Furness, J. C.]]></dc:creator>
<dc:date>2012-04-27T02:02:41-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201987</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201987</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Acronyms, pneumothoraces and the impact of international health on the NHS]]></dc:title>
<prism:publicationDate>2012-04-27</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201484v1?rss=1">
<title><![CDATA[Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201484v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>Small airways function studies in lung disease have used three promising multiple breath washout (MBW) derived indices: indices of ventilation heterogeneity in the acinar (S<SUB>acin</SUB>) and conductive (S<SUB>cond</SUB>) lung zones, and the lung clearance index (LCI). Since peripheral lung structure is known to change with age, ventilation heterogeneity is expected to be affected too. However, the age dependence of the MBW indices of ventilation heterogeneity in the normal lung is unknown.</p></sec><sec><st>Objectives</st><p>The authors systematically investigated S<SUB>acin</SUB>, S<SUB>cond</SUB> or LCI as a function of age, testing also the robustness of these relationships across two laboratories.</p></sec><sec><st>Methods</st><p>MBW tests were performed by never-smokers (50% men) in the age range 25&ndash;65&nbsp;years, with data gathered across two laboratories (n=120 and n=60). For comparison with the literature, the phase III slopes from classical single breath washout tests were also acquired in one group (n=120).</p></sec><sec><st>Measurements and main results</st><p>All three MBW indices consistently increased with age, representing a steady worsening of ventilation heterogeneity in the age range 25&ndash;65. Age explained 7&ndash;16% of the variability in S<SUB>acin</SUB> and S<SUB>cond</SUB> and 36% of the variability in LCI. There was a small but significant gender difference only for S<SUB>acin</SUB>. Classical single breath washout phase III slopes also showed age dependencies, with gender effects depending on the normalisation method used.</p></sec><sec><st>Conclusions</st><p>With respect to the clinical response, age is a small but consistent effect that needs to be factored in when using the MBW indices for the detection of small airways abnormality in disease.</p></sec>]]></description>
<dc:creator><![CDATA[Verbanck, S., Thompson, B. R., Schuermans, D., Kalsi, H., Biddiscombe, M., Stuart-Andrews, C., Hanon, S., Van Muylem, A., Paiva, M., Vincken, W., Usmani, O.]]></dc:creator>
<dc:date>2012-04-27T02:02:42-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201484</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201484</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung]]></dc:title>
<prism:publicationDate>2012-04-27</prism:publicationDate>
<prism:section>Exhaled markers</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201140v1?rss=1">
<title><![CDATA[Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201140v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Current guidelines recommend treatment with one or more long-acting bronchodilators for patients with moderate or more severe chronic obstructive pulmonary disease (COPD). The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting &beta;<SUB>2</SUB> agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone.</p></sec><sec><st>Methods</st><p>In two identically designed, double-blind, 12-week studies, patients with moderate to severe COPD were randomised to indacaterol 150&nbsp;&mu;g once daily or matching placebo. All patients concurrently received open-label tiotropium 18&nbsp;&mu;g once daily. The primary outcome was standardised area under the curve of forced expiratory volume in 1&nbsp;s (FEV<SUB>1</SUB>) from 5&nbsp;min to 8&nbsp;h post dose at week 12. The key secondary outcome was 24 h post-dose (&lsquo;trough&rsquo;) FEV<SUB>1</SUB> at week 12. Resting inspiratory capacity (IC) was measured in a subgroup.</p></sec><sec><st>Results</st><p>1134 and 1142 patients were randomised in studies 1 and 2; 94% and 94% completed. Compared with monotherapy, concurrent therapy increased FEV<SUB>1</SUB> (area under the curve by 130 and 120&nbsp;ml, trough by 80 and 70&nbsp;ml; all p&lt;0.001) and trough IC (by 130 and 100&nbsp;ml, p&lt;0.01). Cough was more common with indacaterol plus tiotropium (10% and 9%) than with tiotropium alone (4% and 4%). Most cases (~90%) of cough were mild. Other adverse events were similar for the treatment groups.</p></sec><sec><st>Conclusions</st><p>Compared with tiotropium monotherapy, indacaterol plus tiotropium provided greater bronchodilation and lung deflation (reflected by increased resting IC). Adverse events were similar between treatments apart from mild cough being more common with indacaterol plus tiotropium. These results support COPD guideline recommendations to combine bronchodilators with different mechanisms of action.</p></sec><sec><st>Trial registration numbers</st><p>NCT00846586 and NCT00877383.</p></sec>]]></description>
<dc:creator><![CDATA[Mahler, D. A., D'Urzo, A., Bateman, E. D., Ozkan, S. A., White, T., Peckitt, C., Lassen, C., Kramer, B., on behalf of the INTRUST-1 and INTRUST-2 study investigators]]></dc:creator>
<dc:date>2012-04-27T02:02:41-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201140</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201140</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Airway biology, Lung function]]></dc:subject>
<dc:title><![CDATA[Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison]]></dc:title>
<prism:publicationDate>2012-04-27</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200253v1?rss=1">
<title><![CDATA[Effect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200253v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>This study evaluated the efficacy of a mindfulness training programme (mindfulness-based stress reduction (MBSR)) in improving asthma-related quality of life and lung function in patients with asthma.</p></sec><sec><st>Methods</st><p>A randomised controlled trial compared an 8-week MBSR group-based programme (n=42) with an educational control programme (n=41) in adults with mild, moderate or severe persistent asthma recruited at a university hospital outpatient primary care and pulmonary care clinic. Primary outcomes were quality of life (Asthma Quality of Life Questionnaire) and lung function (change from baseline in 2-week average morning peak expiratory flow (PEF)). Secondary outcomes were asthma control assessed by 2007 National Institutes of Health/National Heart Lung and Blood Institute guidelines, and stress (Perceived Stress Scale (PSS)). Follow-up assessments were conducted at 10&nbsp;weeks, 6 and 12&nbsp;months.</p></sec><sec><st>Results</st><p>At 12&nbsp;months MBSR resulted in clinically significant improvements from baseline in quality of life (differential change in Asthma Quality of Life Questionnaire score for MBSR vs control: 0.66 (95% CI 0.30 to 1.03; p&lt;0.001)) but not in lung function (morning PEF, PEF variability and forced expiratory volume in 1 s). MBSR also resulted in clinically significant improvements in perceived stress (differential change in PSS score for MBSR vs control: &ndash;4.5 (95% CI &ndash;7.1 to &ndash;1.9; p=0.001)). There was no significant difference (p=0.301) in percentage of patients in MBSR with well controlled asthma (7.3% at baseline to 19.4%) compared with the control condition (7.5% at baseline to 7.9%).</p></sec><sec><st>Conclusions</st><p>MBSR produced lasting and clinically significant improvements in asthma-related quality of life and stress in patients with persistent asthma, without improvements in lung function.</p></sec><sec><st>Clinical Trial Registration Number</st><p>Asthma and Mindfulness-Based Reduction (MBSR) Identifier: NCT00682669. <A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>.</p></sec>]]></description>
<dc:creator><![CDATA[Pbert, L., Madison, J. M., Druker, S., Olendzki, N., Magner, R., Reed, G., Allison, J., Carmody, J.]]></dc:creator>
<dc:date>2012-04-27T02:02:41-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200253</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200253</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Airway biology, Asthma, Lung function]]></dc:subject>
<dc:title><![CDATA[Effect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial]]></dc:title>
<prism:publicationDate>2012-04-27</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201758v1?rss=1">
<title><![CDATA[Diagnosing cystic fibrosis: what are we sweating about?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201758v1?rss=1</link>
<description><![CDATA[<p>Over the last few decades, the paradigm has shifted as cystic fibrosis (CF) is no longer a fatal disease of childhood and should be considered a chronic condition where survival into adulthood is expected. Median survival for current newborns is predicted to be at least 50&nbsp;years and over 55% of patients in the UK are adults.<cross-ref type="bib" refid="b1">1</cross-ref> Over these decades, our knowledge of the underlying pathophysiology has grown exponentially, from its original description in 1938 to the identification of the mutated gene (<I>cystic fibrosis transmembrane conductance regulator</I>, <I>CFTR</I>) in 1989.<cross-ref type="bib" refid="b2">2</cross-ref> This has driven the development of effective therapies and brought about an increased understanding of the wide spectrum of diseases that result from abnormal CFTR function. During this time, the humble sweat test has remained at the heart of the diagnostic algorithm, with only modest changes from the original pilocarpine iontophoresis technique first described by Gibson and...]]></description>
<dc:creator><![CDATA[Simmonds, N. J., Bush, A.]]></dc:creator>
<dc:date>2012-04-17T02:03:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201758</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201758</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Venous thromboembolism, Asthma, Cystic fibrosis, Pulmonary embolism, Pulmonary hypertension]]></dc:subject>
<dc:title><![CDATA[Diagnosing cystic fibrosis: what are we sweating about?]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201679v1?rss=1">
<title><![CDATA[Target volume settings for home mechanical ventilation: great progress or just a gadget?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201679v1?rss=1</link>
<description><![CDATA[<p>Home mechanical ventilation (HMV) is a well-established treatment option for patients with chronic hypercapnic respiratory failure, whereby non-invasive positive pressure ventilation (NPPV) serves as the predominant means of HMV delivery.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> In general, there are two physiologically-different modes of NPPV deliveries, volume-preset NPPV and pressure-preset NPPV. During volume-preset NPPV a fixed inspiratory volume (V<SUB>insp</SUB>) is set at the ventilator, while the inspiratory positive airway pressure (IPAP) varies depending on airway resistance. Conversely, V<SUB>insp</SUB> varies during pressure-preset NPPV, while IPAP remains fixed. The advantage of volume-preset NPPV is that V<SUB>insp</SUB>, and hence tidal volume, are relatively stable; however, this can lead to a breath-by-breath variation in IPAP levels that can become a burden for the patient, and the leakages that regularly occur during NPPV are not compensated for. In contrast, the V<SUB>insp</SUB> that is delivered during pressure-preset NPPV may be unstable due to increased airway resistance; however,...]]></description>
<dc:creator><![CDATA[Windisch, W., Storre, J. H.]]></dc:creator>
<dc:date>2012-04-15T02:01:33-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201679</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201679</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Mechanical ventilation, Mechanical ventilation, Health education, Obesity (public health)]]></dc:subject>
<dc:title><![CDATA[Target volume settings for home mechanical ventilation: great progress or just a gadget?]]></dc:title>
<prism:publicationDate>2012-04-15</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201028v1?rss=1">
<title><![CDATA[Follow-up of the Finnish Asthma Programme 2000-2010: reduction of hospital burden needs risk group rethinking]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201028v1?rss=1</link>
<description><![CDATA[<p>The Finnish Asthma Programme 1994&ndash;2004 focused on early intervention and disease control, thereby resulting in a significant reduction of asthma morbidity. During the follow-up period from 2000 to 2010, the number of hospital days continued to fall by 54%. Patients &ge;65&nbsp;years, especially women, accounted for 39% of the hospital days, and they need attention if the hospital burden is to be reduced further.</p>]]></description>
<dc:creator><![CDATA[Kauppi, P., Linna, M., Martikainen, J., Makela, M. J., Haahtela, T.]]></dc:creator>
<dc:date>2012-04-15T02:01:33-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201028</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201028</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Follow-up of the Finnish Asthma Programme 2000-2010: reduction of hospital burden needs risk group rethinking]]></dc:title>
<prism:publicationDate>2012-04-15</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201454v1?rss=1">
<title><![CDATA[Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201454v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The American and European cystic fibrosis (CF) guidelines recommend different diagnostic criteria. This study assessed diagnostic concordance between these recommendations.</p></sec><sec><st>Methods</st><p>Subjects with single organ manifestations suggestive of CF (chronic sinopulmonary disease (RESP), chronic/recurrent pancreatitis (PANC) or obstructive azoospermia (AZOOSP)) were prospectively evaluated by sweat test, nasal potential difference and genotyping. Concordance in diagnostic outcomes between the two algorithms was measured using observed agreement and  statistics.</p></sec><sec><st>Results</st><p>A total of 208 subjects were evaluated. Observed agreement was 84.8% and level of agreement was excellent (=0.87) between the American and European recommendations. The RESP phenotype was associated with the highest degree of concordance (observed agreement &ge;90%, =0.92) compared with the PANC (observed agreement 86%, =0.65) and AZOOSP (observed agreement 80%, =0.87) phenotypes. Incorporation of nasal potential difference into the American algorithm failed to improve the overall degree of concordance (good agreement level; =0.75); the level of agreement was unchanged in RESP and PANC subjects, but reduced in AZOOSP subjects (from excellent to good). Extensive genotyping had limited clinical utility in the diagnosis of CF in both algorithms.</p></sec><sec><st>Conclusions</st><p>Despite inconsistencies between the American and European diagnostic recommendations, concordance in diagnostic outcomes among subjects presenting with single organ manifestations of CF was good to excellent. These diagnostic guidelines provide guidance and promote rigorous evaluation for the diagnosis of CF but neither guideline should be regarded as dogma.</p></sec>]]></description>
<dc:creator><![CDATA[Ooi, C. Y., Dupuis, A., Ellis, L., Jarvi, K., Martin, S., Gonska, T., Dorfman, R., Kortan, P., Solomon, M., Tullis, E., Durie, P. R.]]></dc:creator>
<dc:date>2012-04-15T02:01:33-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201454</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201454</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?]]></dc:title>
<prism:publicationDate>2012-04-15</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201868v1?rss=1">
<title><![CDATA[A rapidly growing lung mass with air crescent formation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201868v1?rss=1</link>
<description><![CDATA[<sec><st>Pulmonary puzzle</st><p>A 58-year-old man who never smoked and was under follow-up for polymyositis associated with fibrotic interstitial lung disease was found to have an incidental opacity in the right upper lobe on a chest radiograph. He had been treated with daily azathioprine 200&nbsp;mg and prednisolone 10&nbsp;mg for 15&nbsp;years. A CT chest revealed a mass-like lesion of relatively low attenuation suggesting necrosis (<cross-ref type="fig" refid="fig1">figure 1</cross-ref>). Bronchoalveolar lavage was negative for microbiology and cytology. CT-guided biopsies were reported as showing necrosis and inflammation only. A month later, he developed cough with malodorous sputum, generalised fatigue, mild fevers, sweats and dyspnoea.</p><p>Two months after the first CT, at presentation to our unit, the patient experienced small haemoptyses. Subsequent chest high resolution CT showed a marked increase in size of the lesion and eccentric cavitation (air crescent sign) (<cross-ref type="fig" refid="fig2">figure 2</cross-ref>). Bronchoscopic lavage and endobronchial biopsies remained non-diagnostic. Multiple CT-guided cutting needle biopsies...]]></description>
<dc:creator><![CDATA[Lota, H. K., Dusmet, M., Steele, K., Wells, A. U., Nicholson, A. G., Hansell, D. M., Renzoni, E. A.]]></dc:creator>
<dc:date>2012-04-13T02:03:58-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201868</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201868</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Hemoptysis, Lung neoplasms, Pulmonary eosinophilia, Muscle disease, Neuromuscular disease, Lung cancer (oncology), Chemotherapy, Screening (oncology), Inflammation, Lung cancer (respiratory medicine), Interstitial lung disease, Vascularitis, Cardiothoracic surgery, Radiology (diagnostics), Health education, Smoking, Health effects of tobacco use, Tobacco use]]></dc:subject>
<dc:title><![CDATA[A rapidly growing lung mass with air crescent formation]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201309v1?rss=1">
<title><![CDATA[Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201309v1?rss=1</link>
<description><![CDATA[<p>Despite decades of research, no specific pharmacological therapy to treat acute lung injury (ALI) has been identified. At present, the only effective therapies act by limiting iatrogenic injury associated with positive fluid balance<cross-ref type="bib" refid="b1">1</cross-ref> or mechanical ventilation.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> As efforts to pharmacologically modulate the complex inflammatory process which leads to alveolar injury have been unsuccessful,<cross-ref type="bib" refid="b4">4</cross-ref> focus has changed to cell based therapy, aimed at utilising stems cells which have pleiotropic effects and which respond appropriately to local signalling molecules.</p><p>Stem cells have the capacity for limitless self-renewal and differentiation. Mesenchymal stem cells (MSC) are multipotent adult stem cells with the capacity to differentiate into many different cell types, including alveolar cells. There are several mechanisms through which MSCs could potentially be used for attenuating lung injury and augmenting repair.<cross-ref type="bib" refid="b5">5</cross-ref> On the basis of the currently available data, and supported by two papers,<cross-ref...]]></description>
<dc:creator><![CDATA[Mac Sweeney, R., McAuley, D. F.]]></dc:creator>
<dc:date>2012-04-13T02:03:59-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201309</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201309</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Adult respiratory distress syndrome, Drugs: infectious diseases, Pneumonia (infectious disease), TB and other respiratory infections, Inflammation, Mechanical ventilation, Mechanical ventilation, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?]]></dc:title>
<prism:publicationDate>2012-04-13</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200863v1?rss=1">
<title><![CDATA[Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200863v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The death receptor ligand tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) shows considerable clinical promise as a therapeutic agent. TRAIL induces leukocyte apoptosis, reducing acute inflammatory responses in the lung. It is not known whether TRAIL modifies chronic lung injury or whether TRAIL has a role in human idiopathic pulmonary fibrosis (IPF). We therefore explored the capacity of TRAIL to modify chronic inflammatory lung injury and studied TRAIL expression in patients with IPF.</p></sec><sec><st>Methods</st><p>TRAIL<sup>&ndash;/&ndash;</sup> and wild-type mice were instilled with bleomycin and inflammation assessed at various time points by bronchoalveolar lavage and histology. Collagen deposition was measured by tissue hydroxyproline content. TRAIL expression in human IPF lung samples was assessed by immunohistochemistry and peripheral blood TRAIL measured by ELISA.</p></sec><sec><st>Results</st><p>TRAIL<sup>&ndash;/&ndash;</sup> mice had an exaggerated delayed inflammatory response to bleomycin, with increased neutrophil numbers (mean 3.19&plusmn;0.8 wild type vs 11.5&plusmn;5.4<FONT FACE="arial,helvetica">x</FONT>10<sup>4</sup> TRAIL<sup>&ndash;/&ndash;</sup>, p&lt;0.0001), reduced neutrophil apoptosis (5.42&plusmn;1.6% wild type vs 2.47&plusmn;0.5% TRAIL<sup>&ndash;/&ndash;</sup>, p=0.0003) and increased collagen (3.45&plusmn;0.2 wild type vs 5.8&plusmn;1.3&nbsp;mg TRAIL<sup>&ndash;/&ndash;</sup>, p=0.005). Immunohistochemical analysis showed induction of TRAIL in bleomycin-treated wild-type mice. Patients with IPF demonstrated lower levels of TRAIL expression than in control lung biopsies and their serum levels of TRAIL were significantly lower compared with matched controls (38.1&plusmn;9.6 controls vs 32.3&plusmn;7.2&nbsp;pg/ml patients with IPF, p=0.002).</p></sec><sec><st>Conclusion</st><p>These data suggest TRAIL may exert beneficial, anti-inflammatory actions in chronic pulmonary inflammation in murine models and that these mechanisms may be compromised in human IPF.</p></sec>]]></description>
<dc:creator><![CDATA[McGrath, E. E., Lawrie, A., Marriott, H. M., Mercer, P., Cross, S. S., Arnold, N., Singleton, V., Thompson, A. A. R., Walmsley, S. R., Renshaw, S. A., Sabroe, I., Chambers, R. C., Dockrell, D. H., Whyte, M. K. B.]]></dc:creator>
<dc:date>2012-04-11T02:01:17-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200863</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200863</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Chemotherapy, Inflammation, Interstitial lung disease]]></dc:subject>
<dc:title><![CDATA[Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis]]></dc:title>
<prism:publicationDate>2012-04-11</prism:publicationDate>
<prism:section>Interstitial lung disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201720v1?rss=1">
<title><![CDATA[Spirometric definition of COPD: exercise in futility or factual debate?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201720v1?rss=1</link>
<description><![CDATA[<p>The current international guidelines for the diagnosis and management of COPD recognise spirometry as a major criterion to confirm a clinical diagnosis of COPD.<cross-ref type="bib" refid="b1">1&ndash;3</cross-ref><cross-ref type="bib" refid="b2"></cross-ref><cross-ref type="bib" refid="b3"></cross-ref> The specific role of spirometry for the diagnosis of COPD is to identify the presence if airflow obstruction, which is the essential requirement for the definition of the disease. Although a reduction of the ratio of forced expiratory volume in one second (FEV<SUB>1</SUB>) to forced vital capacity (FVC) has been consistently adopted as an unquestionable sign of airflow obstruction, no consensus has been achieved regarding the cut-off to separate healthy from obstructed subjects.</p><p>In 1986 the American Thoracic Society (ATS) suggested an obstructive abnormality be present when FEV<SUB>1</SUB>/FVC is &lt;0.75 independent of age and sex.<cross-ref type="bib" refid="b4">4</cross-ref> By contrast, the European Respiratory Society (ERS) recommended the use of the ratio of FEV<SUB>1</SUB> to slow vital capacity (VC) with cut-off values as...]]></description>
<dc:creator><![CDATA[Brusasco, V.]]></dc:creator>
<dc:date>2012-03-30T02:01:08-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201720</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201720</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Airway biology, Asthma, Lung function, Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Spirometric definition of COPD: exercise in futility or factual debate?]]></dc:title>
<prism:publicationDate>2012-03-30</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200690v1?rss=1">
<title><![CDATA[Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200690v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>Antielastin autoimmunity has been hypothesised to drive disease progression in chronic obstructive pulmonary disease (COPD). The proposed mechanism is currently disputed by conflicting data. The authors aimed to explore antibody responses against elastin in a large and extensively characterised COPD population and to assess elastin-specific peripheral T-cell reactivity in a representative subgroup.</p></sec><sec><st>Methods</st><p>Antielastin antibodies were analysed with indirect ELISA on the plasma of 320 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease 1&ndash;4) and 143 smoking controls. In a second group of 40 patients with COPD and smoking controls, T-cell responses against extracellular matrix (elastin, collagen I and collagen V) were determined with enzyme-linked immunosorbent spot (EliSpot) (interferon  (IFN) and interleukin-2) on peripheral blood mononuclear cells and compared with the responses of 11 never-smoking controls.</p></sec><sec><st>Results</st><p>Antielastin antibody titres were not elevated in patients with COPD compared with smoking controls and even decreased significantly with increasing severity of COPD (p&lt;0.001). Lower antielastin antibody titres were also found in a subgroup of patients with CT-proven emphysema. Elastin-specific INF-mediated T helper 1 responses could not be revealed in smoking subjects with and without COPD. Collagen I-mediated T-cell responses were also absent, which contrasted with a significant increased anticollagen V response in the smoking controls and patients with COPD compared with the never smokers (p=0.008). Collagen V-mediated T-cell responses could not discriminate between patients with COPD and smoking controls.</p></sec><sec><st>Conclusion</st><p>A systemic immune response against elastin could not be identified in patients with COPD. By contrast, collagen V-mediated autoimmunity was increased in the subgroup of smokers and may potentially contribute to the pathogenesis of COPD.</p></sec>]]></description>
<dc:creator><![CDATA[Rinaldi, M., Lehouck, A., Heulens, N., Lavend'Homme, R., Carlier, V., Saint-Remy, J.-M., Decramer, M., Gayan-Ramirez, G., Janssens, W.]]></dc:creator>
<dc:date>2012-03-22T02:03:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200690</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200690</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease]]></dc:title>
<prism:publicationDate>2012-03-22</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201739v2?rss=1">
<title><![CDATA[Pneumococcal capsular serotypes and lung infection]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201739v2?rss=1</link>
<description><![CDATA[<p><I>Streptococcus pneumoniae</I> is second only to <I>Mycobacterium tuberculosis</I> as a bacterial cause of worldwide mortality. Unlike <I>M tuberculosis</I>, <I>S pneumoniae</I> remains a major cause of death in the developed world, with a standardised mortality rate of 25 per 100 000 in the UK. <I>S pneumoniae</I> is the commonest pathogen causing community acquired pneumonia (CAP),<cross-ref type="bib" refid="b1">1</cross-ref> and the majority of serious <I>S pneumoniae</I> infections are cases of CAP in infants and older people. <I>S pneumoniae</I> is also an important cause of septicaemia, meningitis and infective exacerbations of chronic obstructive pulmonary disease and bronchiectasis. <I>S pneumoniae</I> is surrounded by an extracellular layer of polysaccharide called the capsule which promotes immune evasion and is an essential virulence factor.<cross-ref type="bib" refid="b2">2</cross-ref> The structure of the capsule differs between <I>S pneumoniae</I> strains, with 93 variants identifiable by serotyping. Serotype prevalence is unequal, with the majority of disease caused by around 20 common serotypes. Which serotypes...]]></description>
<dc:creator><![CDATA[Brown, J. S.]]></dc:creator>
<dc:date>2012-03-21T02:01:32-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201739</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201739</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung infection, Epidemiologic studies, Drugs: infectious diseases, Pneumonia (infectious disease), TB and other respiratory infections, Vaccination / immunisation, Child health, Inflammation, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Pneumococcal capsular serotypes and lung infection]]></dc:title>
<prism:publicationDate>2012-03-21</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200391v1?rss=1">
<title><![CDATA[Poor air quality in classrooms related to asthma and rhinitis in primary schoolchildren of the French 6 Cities Study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200391v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Relationships between indoor air quality (IAQ) found in schools and the allergic and respiratory health of schoolchildren have been insufficiently explored. A survey was conducted in a large sample of classrooms of primary schools in France to provide objective assessments of IAQ to which young schoolchildren are exposed in classrooms, and to relate exposure to major air pollutants found in classrooms to asthma and allergies of schoolchildren.</p></sec><sec><st>Methods</st><p>Concentrations of fine particles with aerodynamic diameter &le;2.5&nbsp;&mu;m (PM<SUB>2.5</SUB>), nitrogen dioxide (NO<SUB>2</SUB>) and three aldehydes were objectively assessed in 401 randomly chosen classrooms in 108 primary schools attended by 6590 children (mean age 10.4 years, SD &plusmn;0.7) in the French 6 Cities Study. The survey incorporated a medical visit including skin prick testing (SPT) for common allergens, a test for screening exercise-induced asthma (EIA) and a standardised health questionnaire completed by parents.</p></sec><sec><st>Results</st><p>Children were differently exposed to poor air quality in classrooms, with almost 30% being highly exposed according to available standards. After adjusting for confounders, past year rhinoconjunctivitis was significantly associated with high levels of formaldehyde in classrooms (OR 1.19; 95% CI 1.04 to 1.36). Additionally, an increased prevalence of past year asthma was found in the classrooms with high levels of PM<SUB>2.5</SUB> (OR 1.21; 95% CI 1.05 to 1.39), acrolein (OR 1.22; 95% CI 1.09 to 1.38) and NO<SUB>2</SUB> (OR 1.16; 95% CI 0.95 to 1.41) compared with others. The relationship was observed mostly for allergic asthma as defined using SPT. A significant positive correlation was found between EIA and the levels of PM<SUB>2.5</SUB> and acrolein in the same week.</p></sec><sec><st>Conclusions</st><p>In this random sample, air quality in classrooms was poor, varied significantly among schools and cities, and was related to an increased prevalence of clinical manifestations of asthma and rhinitis in schoolchildren. Children with a background of allergies seemed at increased risk.</p></sec>]]></description>
<dc:creator><![CDATA[Annesi-Maesano, I., Hulin, M., Lavaud, F., Raherison, C., Kopferschmitt, C., de Blay, F., Andre Charpin, D., Denis, C.]]></dc:creator>
<dc:date>2012-03-21T02:01:01-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200391</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200391</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, TB and other respiratory infections, Child health, Asthma, Ear, nose and throat/otolaryngology, Screening (epidemiology), Air pollution, Environmental issues, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Poor air quality in classrooms related to asthma and rhinitis in primary schoolchildren of the French 6 Cities Study]]></dc:title>
<prism:publicationDate>2012-03-21</prism:publicationDate>
<prism:section>Asthma and the environment</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201096v1?rss=1">
<title><![CDATA[The relationship between clinical outcomes and medication adherence in difficult-to-control asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201096v1?rss=1</link>
<description><![CDATA[<p>Medication non-adherence and the clinical implications in difficult-to-control asthma were audited. Prescription issue data from 115 patients identified sub-optimal adherence (&lt;80%) in 65% of patients on inhaled corticosteroids (ICS) or combined ICS/long-acting &beta;2 agonist (LABA). In those using separate ICS and LABA, adherence to LABA (50%) was significantly better than to ICS (14.3%). Patients with sub-optimal ICS adherence had reduced FEV<SUB>1</SUB> and higher sputum eosinophil counts. Adherence ratio was an independent predictor of previous ventilation for acute severe asthma (p=0.008). The majority of patients with difficult-to-control asthma are non-adherent with their asthma medication. Non-adherence is correlated with poor clinical outcomes.</p>]]></description>
<dc:creator><![CDATA[Murphy, A. C., Proeschal, A., Brightling, C. E., Wardlaw, A. J., Pavord, I., Bradding, P., Green, R. H.]]></dc:creator>
<dc:date>2012-03-21T02:01:00-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201096</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201096</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[The relationship between clinical outcomes and medication adherence in difficult-to-control asthma]]></dc:title>
<prism:publicationDate>2012-03-21</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201363v1?rss=1">
<title><![CDATA[Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201363v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Tuberculous pleurisy is traditionally indicated by extreme lymphocytosis in pleural fluid and low yield of effusion culture. However, there is considerable inconsistency among previous study results. In addition, these data should be updated due to early effusion studies and advances in culture methods.</p></sec><sec><st>Methods</st><p>From January 2004 to June 2009, patients with tuberculous pleurisy were retrospectively identified from the mycobacteriology laboratories and the pathology and tuberculosis registration databases of two hospitals in Taiwan where tuberculosis is endemic. Pleural fluid characteristics and yields of mycobacterial cultures using liquid media were evaluated.</p></sec><sec><st>Results</st><p>A total of 382 patients with tuberculous pleurisy were identified. The median lymphocyte percentage of total cells in pleural fluids was 84% (IQR 64&ndash;95%) and 17% of cases had a lymphocyte percentage of &lt;50%. The lymphocyte percentage was negatively associated with the probability of a positive effusion culture (OR 0.97; 95% CI 0.96 to 0.99). The diagnostic yields were 63% for effusion culture, 48% for sputum culture, 79% for the combination of effusion and sputum cultures, and 74% for histological examination of pleural biopsy specimens.</p></sec><sec><st>Conclusion</st><p>The degree of lymphocyte predominance in tuberculous pleurisy was lower than was previously thought. The lymphocyte percentage in pleural fluid was negatively associated with the probability of a positive effusion culture. With the implementation of a liquid culture method, the sensitivity of effusion culture was much higher than has been previously reported, and the combination of effusion and sputum cultures provided a good diagnostic yield.</p></sec>]]></description>
<dc:creator><![CDATA[Ruan, S.-Y., Chuang, Y.-C., Wang, J.-Y., Lin, J.-W., Chien, J.-Y., Huang, C.-T., Kuo, Y.-W., Lee, L.-N., Yu, C.-J. J.]]></dc:creator>
<dc:date>2012-03-21T02:01:00-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201363</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201363</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, TB and other respiratory infections]]></dc:subject>
<dc:title><![CDATA[Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area]]></dc:title>
<prism:publicationDate>2012-03-21</prism:publicationDate>
<prism:section>Tuberculosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201827v1?rss=1">
<title><![CDATA[Tracheobronchial transplantation with a bioartifical nanocomposite]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201827v1?rss=1</link>
<description><![CDATA[<p>This proof-of-concept study describes the transplantation of a tracheobronchial airway with a stem-cell-seeded bioartifical nanocomposite in a 36-year-old man presenting with symptoms consistent of a recurrent primary mucoepidermoid cancer. He had previously been treated with debulking surgery and postoperative radiation. The tumour extension was deemed unresectable, thus, transplant with artificial biomaterial was offered.</p><p>The distal trachea and proximal bronchi were resected for complete tumour removal. The airway was replaced with a synthetic bioartificial nanocomposite, tailor-made in the shape of the patient's airway. The graft was seeded with autologous bone-marrow cells and cultured in a bioreactor for 36&nbsp;h prior to transplantation. An extracellular like matrix and proliferating cells were noted within the graft following incubation. To augment the regeneration process, the patient received granulocyte colony-stimulating factor and epoetin &beta; subcutaneous injections for 2&nbsp;weeks postoperatively. No major complications were encountered and the patient remained asymptomatic and tumour-free 5&nbsp;months later. Postoperative investigations suggested integration...]]></description>
<dc:creator><![CDATA[Sritharan, K.]]></dc:creator>
<dc:date>2012-03-17T02:01:52-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201827</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201827</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Tracheobronchial transplantation with a bioartifical nanocomposite]]></dc:title>
<prism:publicationDate>2012-03-17</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201838v1?rss=1">
<title><![CDATA[High doses of vitamin D may reduce exacerbations of chronic obstructive pulmonary disease]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201838v1?rss=1</link>
<description><![CDATA[<p>There has been much research providing inconsistent evidence for a correlation between low levels of vitamin D and chronic conditions, such as coronary artery disease, multiple sclerosis and diabetes. It is known that vitamin D plays an integral role in the cathelicidin antimicrobial peptide, which serves a critical function in mammalian innate immune defence against invasive bacterial infection. As such, it has been hypothesised that low levels of vitamin D may be important in chronic obstructive pulmonary disease (COPD), in which there is an abnormal inflammatory reaction to inhaled particles and a reduced immune response.</p><p>In this study, the authors recruited 182 patients into a double-blind, randomised, placebo-controlled trial exploring vitamin D supplementation and COPD exacerbations. One hundred and fifty patients completed the study. Patients recruited were either current or former smokers over the age of 50 years, with a diagnosis of moderate to severe COPD. They were randomised to receive...]]></description>
<dc:creator><![CDATA[Heiden, E.]]></dc:creator>
<dc:date>2012-03-16T02:02:47-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201838</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201838</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[High doses of vitamin D may reduce exacerbations of chronic obstructive pulmonary disease]]></dc:title>
<prism:publicationDate>2012-03-16</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201830v1?rss=1">
<title><![CDATA[Autoimmune disorders increase the risk of developing pulmonary embolism]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201830v1?rss=1</link>
<description><![CDATA[<p>This large retrospective study analysed the effect of 33 autoimmune disorders on the risk of developing pulmonary emboli (PE). Five hundred and fifteen thousand one hundred and thirty-seven patients in Sweden with an autoimmune disorder initially diagnosed on hospital admission were identified and retrospectively analysed for PE, between 1964 and 2008.</p><p>Risk of PE increased across all age groups in the first year post admission. Risk gradually decreased after hospitalisation but remained above the control group at 10&nbsp;years post admission. Length of stay did not affect the risk. The thrombotic risk may have been related to active inflammation, side effects of the autoimmune treatment and/or immobilisation. The study postulated that the fall in risk over time was attributable to the inflammatory activity of autoimmune conditions decreasing with effective treatment. Overall risk of PE was lower during 1989&ndash;2008 than during 1964&ndash;1988. Interestingly, no difference was seen after the introduction of low molecular...]]></description>
<dc:creator><![CDATA[Umpleby, H.]]></dc:creator>
<dc:date>2012-03-16T02:02:47-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201830</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201830</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Autoimmune disorders increase the risk of developing pulmonary embolism]]></dc:title>
<prism:publicationDate>2012-03-16</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201321v1?rss=1">
<title><![CDATA[Serum levels and genotype distribution of {alpha}1-antitrypsin in the general population]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201321v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>&alpha;1-Antitrypsin (AAT) deficiency is one of the commonest rare respiratory disorders worldwide. Diagnosis, assessment of risk for developing chronic obstructive pulmonary disease (COPD), and management of replacement therapy require the availability of precise and updated ranges for protein serum levels.</p></sec><sec><st>Objective</st><p>This paper aims to provide ranges of serum AAT according to the main genotype classes in the general population.</p></sec><sec><st>Methods</st><p>The authors correlated mean AAT serum levels with the main <I>SERPINA1</I> variants (M1Ala/M1Val (rs6647), M3 (rs1303), M2/M4 (rs709932), S (rs17580) and Z (rs28929474)) in 6057 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort.</p></sec><sec><st>Results</st><p>The following ranges (5th&ndash;95th percentile) of AAT were found in the serum (g/litre): 1.050&ndash;1.640 for PI*MM, 0.880&ndash;1.369 for PI*MS, 0.730&ndash;1.060 for PI*SS, 0.660&ndash;0.997 for PI*MZ and 0.490&ndash;0.660 for PI*SZ. There was very little overlap in AAT serum levels between genotype classes generally not believed to confer an enhanced health risk (MM and MS) and those associated with an intermediate AAT deficiency and a potentially mildly enhanced health risk (SS, MZ).</p></sec><sec><st>Conclusion</st><p>This work resulted in three important findings: technically updated and narrower serum ranges for AAT according to PI genotype; a suggestion for a population-based &lsquo;protective threshold&rsquo; of AAT serum level, used in decision-making for replacement therapy; and more precise ranges framing the intermediate AAT deficiency area, a potential target for future primary prevention.</p></sec>]]></description>
<dc:creator><![CDATA[Ferrarotti, I., Thun, G. A., Zorzetto, M., Ottaviani, S., Imboden, M., Schindler, C., von Eckardstein, A., Rohrer, L., Rochat, T., Russi, E. W., Probst-Hensch, N. M., Luisetti, M.]]></dc:creator>
<dc:date>2012-03-16T02:02:48-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201321</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201321</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Air pollution, Environmental issues]]></dc:subject>
<dc:title><![CDATA[Serum levels and genotype distribution of {alpha}1-antitrypsin in the general population]]></dc:title>
<prism:publicationDate>2012-03-16</prism:publicationDate>
<prism:section>Alpha-1-antitrypsin deficiency</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201655v2?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201655v2?rss=1</link>
<description><![CDATA[<p>Beckett and Woolhouse have investigated the inequality in access to surgery for individuals with non-small cell lung cancer (NSCLC) in England.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> They have used the number of patients entered into the National Lung Cancer Audit (NLCA) as a surrogate marker for the &lsquo;specialist&rsquo; qualities of the multi-disciplinary team (MDT) and concluded that this marker does not influence surgical resection rate or survival.</p><p>An MDT with a high number of patients may reflect a high level of experience, but this may not be the case for every MDT. It would be helpful to see the actual numbers of patients per MDT in each quintile and the raw data for survival. Only the largest of MDTs may link to specialist qualities. MDTs reviewing a large number of patients, but outside the top quintile, may reflect those that are under-resourced and struggling to cope.</p><p>Other factors that may influence the...]]></description>
<dc:creator><![CDATA[Rich, A., Baldwin, D., Hubbard, R.]]></dc:creator>
<dc:date>2012-03-14T02:01:49-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201655</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201655</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200266v2?rss=1">
<title><![CDATA[Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200266v2?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Although generally mild, the 2009&ndash;2010 influenza A/H1N1 pandemic caused two major surges in hospital admissions in the UK. The characteristics of patients admitted during successive waves are described.</p></sec><sec><st>Methods</st><p>Data were systematically obtained on 1520 patients admitted to 75 UK hospitals between May 2009 and January 2010. Multivariable analyses identified factors predictive of severe outcome.</p></sec><sec><st>Results</st><p>Patients aged 5&ndash;54&nbsp;years were over-represented compared with winter seasonal admissions for acute respiratory infection, as were non-white ethnic groups (first wave only). In the second wave patients were less likely to be school age than in the first wave, but their condition was more likely to be severe on presentation to hospital and they were more likely to have delayed admission. Overall, 45% had comorbid conditions, 16.5% required high dependency (level 2) or critical (level 3) care and 5.3% died. As in 1918&ndash;1919, the likelihood of severe outcome by age followed a W-shaped distribution. Pre-admission antiviral drug use decreased from 13.3% to 10% between the first and second waves (p=0.048), while antibiotic prescribing increased from 13.6% to 21.6% (p&lt;0.001). Independent predictors of severe outcome were age 55&ndash;64&nbsp;years, chronic lung disease (non-asthma, non-chronic obstructive pulmonary disease), neurological disease, recorded obesity, delayed admission (&ge;5&nbsp;days after illness onset), pneumonia, C-reactive protein &ge;100&nbsp;mg/litre, and the need for supplemental oxygen or intravenous fluid replacement on admission.</p></sec><sec><st>Conclusions</st><p>There were demographic, ethnic and clinical differences between patients admitted with pandemic H1N1 infection and those hospitalised during seasonal influenza activity. Despite national policies favouring use of antiviral drugs, few patients received these before admission and many were given antibiotics.</p></sec>]]></description>
<dc:creator><![CDATA[Myles, P. R., Semple, M. G., Lim, W. S., Openshaw, P. J., Gadd, E. M., Read, R. C., Taylor, B. L., Brett, S. J., McMenamin, J., Enstone, J. E., Armstrong, C., Bannister, B., Nicholson, K. G., Nguyen-Van-Tam, J. S., on behalf of the Influenza Clinical Information Network (FLU-CIN)]]></dc:creator>
<dc:date>2012-03-14T02:01:50-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200266</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200266</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Drugs: infectious diseases, Bird flu, Influenza, Pneumonia (infectious disease), TB and other respiratory infections, Pneumonia (respiratory medicine), Health education, Obesity (public health)]]></dc:subject>
<dc:title><![CDATA[Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Respiratory infection</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201829v1?rss=1">
<title><![CDATA[Salbutamol infusion worsens outcomes in ARDS]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201829v1?rss=1</link>
<description><![CDATA[<p>Salbutamol infusion has previously been shown to significantly reduce extravascular lung water in mechanically ventilated patients with acute respiratory distress syndrome (ARDS). This double-blind randomised placebo-controlled study investigated the effects of early salbutamol infusion on the clinical outcome of patients with ARDS. The authors recruited a total of 326 patients from 46 UK intensive care units and randomly assigned them to receive either intravenous salbutamol or placebo for 7&nbsp;days. Exclusion criteria included patients requiring continuous or regular aerosolized &beta;<SUB>2</SUB> agonists and those receiving &beta;-adrenergic antagonists. All other treatment measures were carried out according to local practice. The trial was terminated early due to safety concerns.</p><p>When compared with those in the placebo arm, patients receiving continuous salbutamol infusion demonstrated significantly higher mortality rates at 28&nbsp;days (34% vs 23%, RR 1.47, 95% CI 1.03 to 2.08). There was also a trend towards increased adverse rates necessitating drug withdrawal, including tachycardia (14% vs...]]></description>
<dc:creator><![CDATA[Okafor, O.]]></dc:creator>
<dc:date>2012-03-13T02:06:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201829</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201829</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Salbutamol infusion worsens outcomes in ARDS]]></dc:title>
<prism:publicationDate>2012-03-13</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201828v1?rss=1">
<title><![CDATA[Restoration of function of the {triangleup}F508 mutation in cystic fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201828v1?rss=1</link>
<description><![CDATA[<p>The first nucleotide binding domain (NBD1) of the of F508 cystic fibrosis transmembrane conductance regulator (CFTR), is considered a potential drug target in cystic fibrosis but the links between this and CFTR misfolding remain unclear. NBD1 is one of the cytosolic domains of CFTR and is found in at least one allele of 90% of cystic fibrosis patients, significantly diminishing the folding efficiency of CFTR. The aim of this study was to clarify the role of NBD1 and structural consequences of the F508 mutation in CFTR assembly.</p><p>The isolated domains of thermodynamic and kinetic destabilisation from isolated NBD1 variants by the F508 mutation were studied along with conformational stabilisation of F508 NBD1. Thermodynamic and kinetic destabilisations in combination were shown to be responsible for the F508 NBD1 misfolding. In full-length CFTR, the stability of NBD1 and NBD1-CL interface is needed for normal channel function. As F508 causes impairment of both these...]]></description>
<dc:creator><![CDATA[Rowan, S.]]></dc:creator>
<dc:date>2012-03-13T02:06:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201828</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201828</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Restoration of function of the {triangleup}F508 mutation in cystic fibrosis]]></dc:title>
<prism:publicationDate>2012-03-13</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201092v2?rss=1">
<title><![CDATA[Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201092v2?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The distribution of pneumococcal serotypes implicated in non-invasive community-acquired pneumonia (CAP) in adults is currently unknown.</p></sec><sec><st>Methods</st><p>A prospective observational cohort study was conducted over 2&nbsp;years in a large UK teaching hospital trust. Urine samples, in addition to routine blood and sputum samples, were obtained from consecutive adults admitted to the hospital with CAP. Pneumococcal serotype was determined from urine samples using a validated multiplex immunoassay which detects 14 serotypes.</p></sec><sec><st>Results</st><p>Of 920 patients with CAP, 366 had pneumococcal CAP; 242 had a serotype determined. Thirty-day mortality was 10% for all-cause CAP and 9.6% for pneumococcal CAP. Annual incidence of pneumococcal CAP was 36.5 per 100 000, increasing from 12.1 to 274.1 per 100 000 for ages 16&ndash;44&nbsp;years and &ge;85&nbsp;years, respectively. The most prevalent serotypes were 14, 1, 8, 3 and 19A. Less invasive serotypes were significantly associated with increasing age (OR per increasing age group: 1.5, 95% CI 1.2 to 1.9, p&lt;0.001) and co-morbidity (OR per increasing Charlson index group: 1.4, 95% CI 1.0 to 2.0, p=0.036), and with higher 30-day mortality (OR adjusted for age and co-morbidity: 5.5, 95% CI 1.2 to 25.3, p=0.028) compared with highly invasive serotypes. The proportion of patients in whom serotypes contained within the seven-valent childhood pneumococcal conjugate vaccine was identified increased with age (15.6% for patients aged 16&ndash;44&nbsp;years, 41.0% for patients aged &ge;85&nbsp;years; p&lt;0.05).</p></sec><sec><st>Conclusions</st><p>In adult invasive and non-invasive pneumococcal CAP, the most common serotypes implicated were 14, 1, 8, 3 and 19A. Age and co-morbidity were associated with the distribution of serotypes identified.</p></sec>]]></description>
<dc:creator><![CDATA[Bewick, T., Sheppard, C., Greenwood, S., Slack, M., Trotter, C., George, R., Lim, W. S.]]></dc:creator>
<dc:date>2012-03-10T09:26:21-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201092</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201092</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pneumonia (infectious disease), TB and other respiratory infections, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia]]></dc:title>
<prism:publicationDate>2012-03-10</prism:publicationDate>
<prism:section>Respiratory infection</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201088v1?rss=1">
<title><![CDATA[Pulmonary complications of intravesicular BCG immunotherapy]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201088v1?rss=1</link>
<description><![CDATA[<p>A 79-year-old man was admitted to hospital with fever, rigours and malaise 1&nbsp;week after completing his seventh intravesicular BCG immunotherapy treatment for carcinoma in situ of the bladder. On admission, respiratory examination was normal with a peripheral oxygen saturation of 94% on air and a normal white cell count but raised C reactive protein of 111. His chest radiograph was normal (<cross-ref type="fig" refid="fig1">figure 1</cross-ref>). He was treated for presumed urinary sepsis with intravenous antibiotics while awaiting results of microscopy and culture of urine and blood cultures.</p><p>By day 5, the patient had become progressively breathless requiring high flow oxygen to maintain his oxygen saturations. Urine and blood cultures taken on admission were negative. A repeat chest radiograph revealed new bilateral pulmonary infiltrates (<cross-ref type="fig" refid="fig2">figure 2</cross-ref>). A CT chest was performed which showed bilateral ground glass changes and multiple tiny pulmonary nodules (<cross-ref type="fig" refid="fig3">figure 3</cross-ref>). The differential diagnosis was...]]></description>
<dc:creator><![CDATA[Davies, B., Ranu, H., Jackson, M.]]></dc:creator>
<dc:date>2012-03-10T09:25:58-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201088</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201088</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Journalology, Drugs: infectious diseases, Inflammation, Interstitial lung disease, Cardiothoracic surgery, Radiology (diagnostics), Ethics]]></dc:subject>
<dc:title><![CDATA[Pulmonary complications of intravesicular BCG immunotherapy]]></dc:title>
<prism:publicationDate>2012-03-10</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200018v1?rss=1">
<title><![CDATA[Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200018v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The rapid spread of multidrug-resistant tuberculosis (MDR-TB) has attracted global concerns. This study aimed to identify factors contributing to the high prevalence of MDR-TB in China's Heilongjiang province.</p></sec><sec><st>Methods</st><p>A cross-sectional survey following the WHO/International Union Against Tuberculosis and Lung Disease guidelines was conducted with consecutive recruitment of patients with TB in 30 counties selected at random in Heilongjiang in 2004. A total of 1995 patients were tested for MDR-TB. Factors associated with MDR-TB were identified through multilevel models and traditional logistic regression analysis, along with in-depth interviews with nine patients, five healthcare managers and four doctors.</p></sec><sec><st>Results</st><p>241 patients (12%) were identified with MDR-TB. The retreatment patients were 5.48 times (95% CI 4.04 to 7.44) more likely to have MDR-TB than newly diagnosed patients. The patients who were treated with isoniazid and rifampin for &gt;180&nbsp;days were 4.82 times (95% CI 2.97 to 7.81) more likely to develop MDR-TB than those treated &lt;180&nbsp;days. Age and delay in initiating TB treatment were associated with MDR-TB. Financial burden, poor knowledge and side effects of TB treatment were perceived by the interviewees as influencing factors. Lack of coordination of services, unsatisfactory supervision of treatment and infection control jeopardised the control of MDR-TB.</p></sec><sec><st>Conclusions</st><p>Inappropriate treatment is the most important influencing factor of MDR-TB. Increasing people's awareness of TB, early detection and appropriate treatment of patients with TB should become a priority, which requires strong commitment and collaboration among health organisations and greater compliance with TB treatment guidelines by service providers and patients.</p></sec>]]></description>
<dc:creator><![CDATA[Liang, L., Wu, Q., Gao, L., Hao, Y., Liu, C., Xie, Y., Sun, H., Yan, X., Li, F., Li, H., Fang, H., Ning, N., Cui, Y., Han, L.]]></dc:creator>
<dc:date>2012-03-08T02:01:05-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200018</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200018</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Drugs: infectious diseases]]></dc:subject>
<dc:title><![CDATA[Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China]]></dc:title>
<prism:publicationDate>2012-03-08</prism:publicationDate>
<prism:section>Tuberculosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201469v1?rss=1">
<title><![CDATA[Authors' response: hyperoxia in acute asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201469v1?rss=1</link>
<description><![CDATA[<p>We appreciate the comments by Snelson and Tunnicliffe<cross-ref type="bib" refid="b1">1</cross-ref> regarding our study of the effects of high concentration oxygen therapy in acute exacerbations of asthma.<cross-ref type="bib" refid="b2">2</cross-ref> We concur with the view that the effect of high concentration oxygen therapy on arterial carbon dioxide pressure (PaCO<SUB>2</SUB>) is not clinically relevant in all patients presenting to the emergency department (ED) with acute severe asthma. However, we consider that the 3.9-fold greater risk of patients developing an increase in transcutaneous partial pressure of carbon dioxide (PtCO<SUB>2</SUB>) &ge;8&nbsp;mm&nbsp;Hg (22% vs 6% in the high concentration vs titrated oxygen groups, respectively) is likely to be of clinical relevance in life-threatening asthma. Even in our study, which excluded patients who were unable to speak or perform spirometry due to breathlessness, all 10 patients who had a final PtCO<SUB>2</SUB> &ge;45&nbsp;mm&nbsp;Hg had received high concentration oxygen therapy. These findings suggest that the routine administration of high...]]></description>
<dc:creator><![CDATA[Perrin, K., Wijesinghe, M., Weatherall, M., Beasley, R.]]></dc:creator>
<dc:date>2012-03-06T02:02:49-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201469</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201469</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response: hyperoxia in acute asthma]]></dc:title>
<prism:publicationDate>2012-03-06</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201001v1?rss=1">
<title><![CDATA[Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201001v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Excess visceral adiposity and sleep apnoea are two conditions independently associated with cardiovascular diseases. The two conditions are often combined and are believed to interact in a vicious circle.</p></sec><sec><st>Objectives</st><p>To compare the response of men with visceral obesity with or without sleep apnoea syndrome to a 1-year healthy eating, physical activity/exercise intervention programme.</p></sec><sec><st>Methods</st><p>77 men, selected on the basis of increased waist circumference (&ge;90&nbsp;cm) and dyslipidaemia (triglycerides &ge;1.69 and/or high-density lipoprotein (HDL) cholesterol &lt;1.03&nbsp;mmol/litre), participated in this study. Body composition and fat distribution were assessed by dual-emission X-ray absorptiometry or CT and sleep breathing disorders by home-based polygraphic recording. Cardiorespiratory fitness, plasma adipokines, plasma inflammatory markers, fasting lipoprotein&ndash;lipid profile and oral glucose tolerance test were assessed.</p></sec><sec><st>Results</st><p>After the 1-year lifestyle intervention, the mean oxygen desaturation index (ODI) of the whole sample decreased (&ndash;3&plusmn;13 events/h, p&lt;0.05). Men with sleep apnoea syndrome at baseline (ODI &ge;10 events/h, n=28) showed smaller reductions in body mass index, waist circumference, triglycerides and smaller increases in HDL cholesterol and adiponectin than men without sleep apnoea (ODI &lt;10 events/h, n=49), despite similar compliance to the programme. The higher the baseline ODI and the time spent under 90% saturation, the lower the reductions in fat mass and visceral adiposity, and the smaller the improvement in glucose/insulin homeostasis indices after 1&nbsp;year.</p></sec><sec><st>Conclusions</st><p>Men with sleep apnoea syndrome at baseline had smaller reduction in body weight and less metabolic improvements associated with the lifestyle intervention programme than men without sleep apnoea syndrome.</p></sec>]]></description>
<dc:creator><![CDATA[Borel, A.-L., Leblanc, X., Almeras, N., Tremblay, A., Bergeron, J., Poirier, P., Despres, J.-P., Series, F.]]></dc:creator>
<dc:date>2012-03-06T02:02:48-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201001</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201001</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Sleep disorders (neurology), Sleep disorders (respiratory medicine), Health education, Obesity (public health)]]></dc:subject>
<dc:title><![CDATA[Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity]]></dc:title>
<prism:publicationDate>2012-03-06</prism:publicationDate>
<prism:section>Sleep disordered breathing</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200160v1?rss=1">
<title><![CDATA[Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200160v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>20&ndash;30% of patients with asthma have neutrophilic airway inflammation and reduced responsiveness to steroid therapy. They often have chronic airway bacterial colonisation and <I>Haemophilus influenzae</I> is one of the most commonly isolated bacteria. The relationship between chronic airway colonisation and the development of steroid-resistant neutrophilic asthma is unclear.</p></sec><sec><st>Objectives</st><p>To investigate the relationship between <I>H influenzae</I> respiratory infection and neutrophilic asthma using mouse models of infection and ovalbumin (OVA)-induced allergic airways disease.</p></sec><sec><st>Methods</st><p>BALB/c mice were intratracheally infected with <I>H influenzae</I> (day 10), intraperitoneally sensitised (day 0) and intranasally challenged (day 12&ndash;15) with OVA. Treatment groups were administered dexamethasone intranasally during OVA challenge. Infection, allergic airways disease, steroid sensitivity and immune responses were assessed (days 11, 16 and 21).</p></sec><sec><st>Results</st><p>The combination of <I>H influenzae</I> infection and allergic airways disease resulted in chronic lung infection that was detected on days 11, 16 and 21 (21, 26 and 31&nbsp;days after infection). Neutrophilic allergic airways disease and T helper 17 cell development were induced, which did not require active infection. Importantly, all features of neutrophilic allergic airways disease were steroid resistant. Toll-like receptor 4 expression and activation of phagocytes was reduced, but most significantly the influx and/or development of phagocytosing neutrophils and macrophages into the airways was inhibited.</p></sec><sec><st>Conclusions</st><p>The combination of infection and allergic airways disease promotes bacterial persistence, leading to the development of a phenotype similar to steroid-resistant neutrophilic asthma and which may result from dysfunction in innate immune cells. This indicates that targeting bacterial infection in steroid-resistant asthma may have therapeutic benefit.</p></sec>]]></description>
<dc:creator><![CDATA[Essilfie, A.-T., Simpson, J. L., Dunkley, M. L., Morgan, L. C., Oliver, B. G., Gibson, P. G., Foster, P. S., Hansbro, P. M.]]></dc:creator>
<dc:date>2012-03-03T02:01:54-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200160</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200160</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung infection, Drugs: infectious diseases, TB and other respiratory infections, Inflammation, Asthma]]></dc:subject>
<dc:title><![CDATA[Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma]]></dc:title>
<prism:publicationDate>2012-03-03</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201549v1?rss=1">
<title><![CDATA['To CT or not to CT? That is the question': outcome surrogates for surveillance in childhood cystic fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201549v1?rss=1</link>
<description><![CDATA[<p>The benefit of the increasing utility of CT has been promoted as a potential long-term outcome surrogate for monitoring patients with cystic fibrosis (CF), and is recognised as a crucial part of CF research.<cross-ref type="bib" refid="b1">1</cross-ref> The study by the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) on the use of thin-section CT highlights the sensitivity of this imaging modality in providing insight into the early development of CF lung disease. The factors associated with the development and progression of structural lung disease in infants and preschool children diagnosed by the newborn CF screening programme<cross-ref type="bib" refid="b2">2</cross-ref> are described.</p><p>The argument for the increasing use of annual CT of the thorax as an outcome surrogate for measuring and monitoring the progression of lung disease in patients with CF is the ability of CT to detect subtle, salient lung parenchymal changes, as opposed to using conventional plain chest radiography...]]></description>
<dc:creator><![CDATA[Young, C., Owens, C.]]></dc:creator>
<dc:date>2012-03-03T02:01:54-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201549</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201549</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Cystic fibrosis, Radiology (diagnostics), Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA['To CT or not to CT? That is the question': outcome surrogates for surveillance in childhood cystic fibrosis]]></dc:title>
<prism:publicationDate>2012-03-03</prism:publicationDate>
<prism:section>Editorials</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201524v1?rss=1">
<title><![CDATA[Cardiovascular armamentarium in a patient with bronchopulmonary fistula]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201524v1?rss=1</link>
<description><![CDATA[<sec><st>Case report</st><p>A 55-year-old patient with non-small-cell lung cancer suffered from productive cough due to bronchopulmonary fistula (BPF) following pneumectomy (<cross-ref type="fig" refid="fig1">figure 1A,B</cross-ref>). First, we used vascular occlusion coils (Tornado Platin Embolization Coils, Cook, Limerick, Ireland, traditionally used for embolisation of selective vessel supply to arteriovenous malformations) placed endobronchially in conjunction with fibrin glue application (<cross-ref type="fig" refid="fig1">figure 1C</cross-ref>). However, the occluding material was expectorated only 1&nbsp;week later, probably due to the size of the fistula (10&nbsp;mm). Second, an Amplatzer vascular plug IV (St. Jude Medical, St. Paul, Minnesota, USA, made of nitinol wires and used for transcatheter embolisation in the peripheral vasculature and occlusion of abnormal vessel communications) was delivered into the fistula (<cross-ref type="fig" refid="fig1">figure 1D</cross-ref>). A few weeks later, a bronchography could assure correct device positioning and sealing of the BPF; however, a second small BPF was visualised. Third, an Angio-Seal (St. Jude Medical, St. Paul, Minnesota,...]]></description>
<dc:creator><![CDATA[Buermann, J., Skowasch, D., Wilhelm, K. E.]]></dc:creator>
<dc:date>2012-03-03T02:01:54-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201524</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201524</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Journalology, Lung neoplasms, Lung cancer (oncology), Screening (oncology), Lung cancer (respiratory medicine), Cardiothoracic surgery, Radiology (diagnostics), Ethics]]></dc:subject>
<dc:title><![CDATA[Cardiovascular armamentarium in a patient with bronchopulmonary fistula]]></dc:title>
<prism:publicationDate>2012-03-03</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201683v1?rss=1">
<title><![CDATA[Authors' response: exposing children to secondhand smoke]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201683v1?rss=1</link>
<description><![CDATA[<p>Pool and colleagues make an important point about exposure to tobacco smoke<cross-ref type="bib" refid="b1">1</cross-ref> but we are uncertain of the relevance to our paper,<cross-ref type="bib" refid="b2">2</cross-ref> which reported the effects of smoking by parents as a behaviour rather than source of passive exposure. While we cannot discount the possibility that children of smokers are more likely to become smokers as a consequence of passive smoke exposure, our interpretation is that it is the behaviour that is responsible.</p><p><fn><no>Competing interests</no><p>None.</p></fn></p><p><fn><no>Provenance and peer review</no><p>Commissioned; externally peer reviewed.</p></fn></p>]]></description>
<dc:creator><![CDATA[Britton, J., Leonardi-Bee, J.]]></dc:creator>
<dc:date>2012-03-01T02:03:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201683</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201683</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response: exposing children to secondhand smoke]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201726v1?rss=1">
<title><![CDATA[Histamine-releasing factor: a possible future therapeutic target for asthma and allergy]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201726v1?rss=1</link>
<description><![CDATA[<p>Mast cells and basophils are key players in the IgE-dependent allergic response. These cells trigger an inflammatory cascade by secreting numerous preformed pro-inflammatory chemical mediators such as histamine, proteases and cytokines into the blood. Histamine-releasing factor (HRF), found in nasal, skin blister and bronchoalveolar lavage fluids, is a protein secreted by macrophages that can stimulate histamine, interleukin 4 and IL-3 production from IgE-sensitised basophils and mast cells. Despite considerable efforts, research has failed to identify a HRF receptor. However, HRF is known to have intracellular and extracellular functions, with the latter implicated in late-phase allergic reactions and chronic inflammation.</p><p>This study identified a subset of IgE and IgG antibodies as HRF-interacting molecules in vitro. Through complex molecular research techniques it was confirmed that HRF together with HRF-reactive IgE triggered mast cell activation in vitro, confirming its pro-inflammatory role. Specific HRF inhibitor peptides were also characterised. Through several different intricate experiments these...]]></description>
<dc:creator><![CDATA[Beasley, V. E.]]></dc:creator>
<dc:date>2012-03-01T02:03:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201726</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201726</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Histamine-releasing factor: a possible future therapeutic target for asthma and allergy]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201703v1?rss=1">
<title><![CDATA[Author's response: allergic rhinitis and asthma require an integrated management]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201703v1?rss=1</link>
<description><![CDATA[<p>I thank Drs Camargos and colleagues for their comments<cross-ref type="bib" refid="b1">1</cross-ref> regarding our paper.<cross-ref type="bib" refid="b2">2</cross-ref> I agree with our Brazilian colleagues that additional randomised controlled trials are needed assessing the effect of allergic rhinitis treatment on asthma control in children.</p><p>In the study by Camargos <I>et al</I>, steroid naive asthmatic patients received fluticasone propionate either through a face mask, while breathing through their nose with their mouth closed, or through a spacer with a mouthpiece for oral inhalation. The latter group also received 0.9% sodium chloride intranasal spray.<cross-ref type="bib" refid="b3">3</cross-ref> Although asthma clinical score, forced expiratory volume in 1's, allergic rhinitis symptom score and nasal inspiratory peak flow improved in both groups from baseline, no statistically significant difference was found between the two treatment groups, except for rhinitis symptom score and nasal inspiratory peakflow at 8&nbsp;weeks in favour of the experimental group (p&lt;0.001 and p=0.008). Because all patients were steroid...]]></description>
<dc:creator><![CDATA[de Groot, E.]]></dc:creator>
<dc:date>2012-03-01T02:03:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201703</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201703</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Author's response: allergic rhinitis and asthma require an integrated management]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201384v1?rss=1">
<title><![CDATA[Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis of the Health Survey for England]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201384v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Some previous studies suggest there are sex differences in susceptibility to, and prevalence of, chronic obstructive pulmonary disease (COPD) but findings are inconsistent. In this study, whether different diagnostic criteria for COPD may contribute to these conflicting findings was examined.</p></sec><sec><st>Methods</st><p>Cross sectional analysis of data from the 1995, 1996 and 2001 Health Survey for England was undertaken, including participants of white ethnicity, aged 40+ years with a valid smoking history and lung function data. COPD was defined using Global Initiative for Chronic Obstructive Lung Disease (GOLD), National Institute for Health and Clinical Excellence (NICE) and lower limit of normal (LLN) spirometric criteria, in the absence of a diagnosis of asthma.</p></sec><sec><st>Results</st><p>COPD was present in 3035 (16.1%), 1304 (7.0%) and 1684 (9.0%) people, according to the GOLD, NICE and LLN criteria, respectively. With both the GOLD and NICE definitions, men had significant independent increased risks of COPD compared with women (OR 1.46 (95% CI 1.34 to 1.59) and 1.30 (1.15 to 1.48), respectively). With the LLN definition, this effect was removed (OR 0.96 (0.87 to 1.07). With the use of both the GOLD and NICE criteria, women had significantly greater susceptibility to COPD (25&ndash;30% higher risk) for the same level of pack years of exposure. This was not observed with the LLN criteria.</p></sec><sec><st>Conclusions</st><p>The study indicates that sex differences in risk of COPD reported in previous studies are influenced by the definition used for COPD. When using a statistically driven definition (LLN), no independent sex difference was found and there was no evidence of an increased susceptibility to COPD among female compared with male smokers.</p></sec>]]></description>
<dc:creator><![CDATA[Jordan, R. E., Miller, M. R., Lam, K.-b. H., Cheng, K. K., Marsh, J., Adab, P.]]></dc:creator>
<dc:date>2012-03-01T02:03:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201384</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201384</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health policy, Asthma, Health service research, Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Sex, susceptibility to smoking and chronic obstructive pulmonary disease: the effect of different diagnostic criteria. Analysis of the Health Survey for England]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201193v1?rss=1">
<title><![CDATA[Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201193v1?rss=1</link>
<description><![CDATA[<p><I>Resident:</I> I would like to present the case of one of my new patients. She is a 63-year-old Caucasian woman with long-term sarcoidosis of the lungs and multiorgan involvement including liver and spleen. Despite pneumological surveillance and prednisolone treatment, her respiratory situation worsened, and was started on home oxygen treatment 5&nbsp;years ago when fibrosis of the lungs was diagnosed. She also has severe osteoporosis due to long-term steroid use and immobility. She is now presenting with worsening dyspnoea of a duration of 4&nbsp;months despite using 8&nbsp;litres of oxygen.</p><p>I admitted a prematurely aged woman in a poor general condition. She presented with dyspnoea, right upper quadrant abdominal pain and back pain. A physical examination revealed stigmata of hypoxaemia, light crackles on both lungs, clinical signs for steroid use and an enlarged liver painful on palpation. She is a non-smoker and she has no history of cardiac diseases or cardiac involvement by...]]></description>
<dc:creator><![CDATA[Nistal, M. W., Pace, A., Klose, H., Benten, D., Lohse, A. W.]]></dc:creator>
<dc:date>2012-03-01T02:03:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201193</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201193</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Pneumonia (infectious disease), TB and other respiratory infections, Child health, Inflammation, Drugs misuse (including addiction), Interstitial lung disease, Pneumonia (respiratory medicine), Pulmonary hypertension, Osteoporosis, Radiology (diagnostics), Health education]]></dc:subject>
<dc:title><![CDATA[Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201081v1?rss=1">
<title><![CDATA[Volume targeted versus pressure support non-invasive ventilation in patients with super obesity and chronic respiratory failure: a randomised controlled trial]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201081v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>Automatic titration modes of non-invasive ventilation, including average volume assured pressure support (AVAPS), are hybrid technologies that target a set volume by automated adjustment of pressure support (PS). These automated modes could offer potential advantages over fixed level PS, in particular, in patients who are super obese.</p></sec><sec><st>Methods</st><p>Consecutive patients with obesity hypoventilation syndrome were enrolled in a two-centre prospective single-blind randomised controlled trial of AVAPS versus fixed-level PS using a strict protocolised setup.</p></sec><sec><st>Measurements</st><p>The primary outcome was change in daytime arterial PCO<SUB>2</SUB> (PaCO<SUB>2</SUB>) at 3&nbsp;months. Body composition, physical activity (7-day actigraphy) and health-related quality of life (severe respiratory insufficiency questionnaire, SRI) were secondary outcome measures.</p></sec><sec><st>Results</st><p>50 patients (body mass index 50&plusmn;7&nbsp;kg/m<sup>2</sup>; 55&plusmn;11&nbsp;years; 53% men) were enrolled with a mean PaCO<SUB>2</SUB> of 6.9&plusmn;0.8&nbsp;kPa and SRI of 53&plusmn;17. 46 patients (23 AVAPS and 23 PS) completed the trial. At 3&nbsp;months, improvements in PaCO<SUB>2</SUB> were observed in both groups (AVAPS 0.6&nbsp;kPa, 95% CI 0.2 to 1.1, p&lt;0.01 vs PS 0.6&nbsp;kPa, 95% CI 0.1 to 1.1, p=0.02) but no between-group difference (&ndash;0.1&nbsp;kPa, 95% CI &ndash;0.7 to 0.6, p=0.87). SRI also improved in both groups (AVAPS 11, 95% CI 6 to 17, p&lt;0.001 vs PS 7, 95% CI 1 to 12, p=0.02; between groups 5, 95% CI &ndash;3 to 12, p=0.21). Secondary analysis of both groups combined showed improvements in daytime physical activity that correlated with reduction in fat mass (r=0.48; p=0.01).</p></sec><sec><st>Conclusion</st><p>The study demonstrated no differences between automated AVAPS mode and fixed-level PS mode using a strict protocolised setup in patients who were super obese. The data suggest that the management of sleep-disordered breathing may enhance daytime activity and promote weight loss in super-obese patients. Trial registration details available at <A HREF="http://www.controlled-trials.com/ISRCTN63940700">http://www.controlled-trials.com/ISRCTN63940700</A></p></sec>]]></description>
<dc:creator><![CDATA[Murphy, P. B., Davidson, C., Hind, M. D., Simonds, A., Williams, A. J., Hopkinson, N. S., Moxham, J., Polkey, M., Hart, N.]]></dc:creator>
<dc:date>2012-03-01T02:03:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201081</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201081</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Sleep disorders (neurology), Sleep disorders, Airway biology, Sleep disorders (respiratory medicine), Health education, Obesity (public health)]]></dc:subject>
<dc:title><![CDATA[Volume targeted versus pressure support non-invasive ventilation in patients with super obesity and chronic respiratory failure: a randomised controlled trial]]></dc:title>
<prism:publicationDate>2012-03-01</prism:publicationDate>
<prism:section>Sleep disordered breathing</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201512v1?rss=1">
<title><![CDATA[CFTR potentiator for cystic fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201512v1?rss=1</link>
<description><![CDATA[<p>This multicentre, double blinded, randomised controlled trial assessed the efficacy of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) protein potentiator.</p><p>The primary outcome of the trial was the change in the forced expiratory volume in 1&nbsp;s (FEV<SUB>1</SUB>). The secondary outcomes were time to the first pulmonary exacerbation and subject-reported respiratory symptoms. The trial included 161 subjects who were 12&nbsp;years of age or above with the G551D mutation.</p><p>The study showed a treatment effect of 10.6% in FEV<SUB>1</SUB> (p&lt;0.001) in patients with a starting FEV<SUB>1</SUB> &lt;70% predicted. There was a 55% reduction in the risk of pulmonary exacerbation and a statistically significant improvement in subject-reported respiratory symptoms by 48&nbsp;weeks. The study showed no significantly increased rate of adverse effects or dropout rate associated with ivacaftor. The study was not powered to assess the treatment effects in different demographic subgroups.</p><p>The G551D mutation is present only in approximately 4%&ndash;5% of cystic fibrosis patients and...]]></description>
<dc:creator><![CDATA[Cho, S. P.]]></dc:creator>
<dc:date>2012-02-29T02:01:40-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201512</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201512</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[CFTR potentiator for cystic fibrosis]]></dc:title>
<prism:publicationDate>2012-02-29</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200832v1?rss=1">
<title><![CDATA[Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200832v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p><I>Pseudomonas aeruginosa</I> chronic pulmonary infection is an unfavourable event in cystic fibrosis. Bacterial clearance is possible with an early antibiotic treatment upon pathogen isolation. Currently, no best practice exists for early treatment. The efficacy of two different regimens against initial <I>P aeruginosa</I> infection was assessed.</p></sec><sec><st>Methods</st><p>In a randomised, open-label, parallel-group study involving 13 centres, the superiority of inhaled tobramycin/oral ciprofloxacin compared with inhaled colistin/oral ciprofloxacin (reference treatment) over 28&nbsp;days was evaluated. Patients were eligible if they were older than 1&nbsp;year with first or new <I>P aeruginosa</I> isolation. Treatments were assigned equally by centralised balanced randomisation, stratified by age and forced expiratory volume in 1 s values. The participants and those giving the intervention were not masked to arm assignments. The primary endpoint was <I>P aeruginosa</I> eradication, defined as three successive negative cultures in 6&nbsp;months. Analysis was by intention to treat. This trial was registered with EudraCT, number 2008-006502-42.</p></sec><sec><st>Results</st><p>105 patients were assigned to inhaled colistin/oral ciprofloxacin (arm A) and 118 to inhaled tobramycin/oral ciprofloxacin (arm B). All patients were analysed. <I>P aeruginosa</I> was eradicated in 66 (62.8%) patients in arm A and in 77 (65.2%) in arm B (OR 0.90, 95% CI 0.52 to 1.55, p=0.81). Following treatment, an increase in <I>Stenotrophomonas maltophilia</I> was noted (OR 3.97, 95% CI 2.27 to 6.94, p=0.001) with no differences between the two arms (OR 0.89, 95% CI 0.44 to 1.78, p=0.88).</p></sec><sec><st>Conclusions</st><p>No superiority of treatment under study was demonstrated in comparison to the reference treatment. Early eradication treatment was associated with an increase in <I>S maltophilia</I>.</p></sec>]]></description>
<dc:creator><![CDATA[Taccetti, G., Bianchini, E., Cariani, L., Buzzetti, R., Costantini, D., Trevisan, F., Zavataro, L., Campana, S., on behalf of the Italian Group for P aeruginosa eradication in cystic fibrosis]]></dc:creator>
<dc:date>2012-02-29T02:01:00-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200832</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200832</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung infection, Drugs: infectious diseases, TB and other respiratory infections, Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols]]></dc:title>
<prism:publicationDate>2012-02-29</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201064v1?rss=1">
<title><![CDATA[Sputum inflammatory phenotypes are not stable in children with asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201064v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Two distinct, stable inflammatory phenotypes have been described in adults with asthma: eosinophilic and non-eosinophilic. Treatment strategies based on these phenotypes have been successful. This study evaluated sputum cytology in children with asthma to classify sputum inflammatory phenotypes and to assess their stability over time.</p></sec><sec><st>Methods</st><p>Sputum induction was performed in 51 children with severe asthma and 28 with mild to moderate asthma. Samples were classified as eosinophilic (&gt;2.5% eosinophils), neutrophilic (&gt;54% neutrophils); mixed granulocytic (&gt;2.5% eosinophils, &gt;54% neutrophils); or paucigranulocytic (&le;2.5% eosinophils, &le;54% neutrophils). Sputum induction was repeated every 3&nbsp;months in children with severe asthma (n=42) over a 1-year period and twice in mild to moderate asthma (n=17) over 3&ndash;6&nbsp;months.</p></sec><sec><st>Results</st><p>62 children (78%) had raised levels of inflammatory cells in at least one sputum sample. In the longitudinal analysis 37 of 59 children (63%) demonstrated two or more phenotypes. Variability in sputum inflammatory phenotype was observed in both the severe and the mild to moderate asthma groups. Change in phenotype was not related to change in inhaled corticosteroid (ICS) dose or asthma control, nor was it reflected in a change in exhaled nitric oxide (FE<SUB>NO</SUB>). 24 children (41%) fulfilled the criteria for non-eosinophilic asthma on one occasion and eosinophilic on another. There were no differences in severity, asthma control, atopy, ICS dose or forced expiratory volume in 1 s between those who were always non-eosinophilic and those always eosinophilic.</p></sec><sec><st>Conclusion</st><p>Raised levels of inflammatory cells were frequently found in children with asthma of all severities. Sputum inflammatory phenotype was not stable in children with asthma.</p></sec>]]></description>
<dc:creator><![CDATA[Fleming, L., Tsartsali, L., Wilson, N., Regamey, N., Bush, A.]]></dc:creator>
<dc:date>2012-02-29T02:00:59-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201064</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201064</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Child health, Asthma, Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[Sputum inflammatory phenotypes are not stable in children with asthma]]></dc:title>
<prism:publicationDate>2012-02-29</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201579v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201579v1?rss=1</link>
<description><![CDATA[<p>In their letter, Thomas and Spencer<cross-ref type="bib" refid="b1">1</cross-ref> claim that our assertion that <I>Staphylococcus aureus</I> is the most important cause of necrotising pneumonia<cross-ref type="bib" refid="b2">2</cross-ref> is wrong on the basis of the most recent evidence and that <I>Streptococcus pneumoniae</I> is currently the major cause.<cross-ref type="bib" refid="b1">1</cross-ref> However, although the studies cited by them document an increase in the incidence of necrotising pneumococcal pneumonia,<cross-ref type="bib" refid="b1">1</cross-ref> we still believe that <I>S aureus</I> is the most important pathogen clinically and therapeutically.</p><p>It has recently been found that the incidence of complicated pneumonia in children is increasing and that there is a concurrent increase in the incidence of community-associated methicillin-resistant <I>S aureus</I> (CA-MRSA) infections.<cross-ref type="bib" refid="b3">3&ndash;5</cross-ref><cross-ref type="bib" refid="b4"></cross-ref><cross-ref type="bib" refid="b5"></cross-ref> The emergence of CA-MRSA was initially reported in the USA and in subjects with skin infections, but paediatric necrotising pneumonia due to <I>S aureus</I> has been reported in healthy subjects of different ages and...]]></description>
<dc:creator><![CDATA[Principi, N., Esposito, S.]]></dc:creator>
<dc:date>2012-02-28T02:05:06-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201579</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201579</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-02-28</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201596v1?rss=1">
<title><![CDATA[Need to test impact of DNA-based risk scores]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201596v1?rss=1</link>
<description><![CDATA[<p>Young and Hopkins highlight the emerging data suggesting that smokers who perceive themselves at a lower risk of lung cancer may be less likely to take part in, and less likely to adhere to, lung cancer screening programmes.<cross-ref type="bib" refid="b1">1&ndash;4</cross-ref><cross-ref type="bib" refid="b2"></cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref> Their work suggesting that a risk score that includes genetic markers of susceptibility of lung cancer alters optimistic bias, improves quit rates in smokers and may encourage participation in lung cancer CT screening is exciting.</p><p>Risk scores that include genetic risk data may reach the parts that other risk scores fail to reach. In the lung-SEARCH screening trial, we found that a negative family history specifically led some smokers to decline participation in screening. Being told that risk of lung cancer is &lsquo;in your genes&rsquo; may specifically counter perceptions of protection from a negative family history. This proposal could be tested with further qualitative exploration...]]></description>
<dc:creator><![CDATA[Griffiths, C., Patel, D., Akporobaro, A., Chinyanganya, N., Hackshaw, A., Seale, C., Walton, R., Spiro, S.]]></dc:creator>
<dc:date>2012-02-28T02:05:06-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201596</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201596</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Need to test impact of DNA-based risk scores]]></dc:title>
<prism:publicationDate>2012-02-28</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200949v1?rss=1">
<title><![CDATA[Systemic elastin degradation in chronic obstructive pulmonary disease]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200949v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Development of emphysema and vascular stiffness in chronic obstructive pulmonary disease (COPD) may be due to a common mechanism of susceptibility to pulmonary and systemic elastin degradation.</p></sec><sec><st>Objectives</st><p>To investigate whether patients with COPD have evidence of systemic elastin degradation in the skin.</p></sec><sec><st>Methods</st><p>The authors measured cutaneous elastin degradation using immunohistochemistry (percentage area of elastin fibres) in sun-exposed (exposed) and non-sun-exposed (non-exposed) skin biopsies in 16 men with COPD and 15 controls matched for age and cigarette smoke exposure. Quantitative PCR of matrix metalloproteinase (MMP)-2, -9, -12 and tissue inhibitor of metalloproteinase-1 mRNA and zymography for protein expression of MMP-2 and -9 were performed on homogenised skin. Arterial stiffness and emphysema severity were measured using carotid-femoral pulse wave velocity and quantitative CT scanning.</p></sec><sec><st>Results</st><p>Skin elastin degradation was greater in exposed and non-exposed skin of patients with COPD compared with controls (exposed, mean (SD); 43.5 (12.1)% vs 26.3 (6.9)%, p&lt;0.001; non-exposed 22.4 (5.2)% vs 18.1 (4.3)%, p=0.02). Cutaneous expression of MMP-9 mRNA and proMMP-9 concentrations was increased in exposed skin of COPD patients (p=0.004 and p=0.02, respectively) and was also associated with increased skin elastin degradation (r=0.62, p&lt;0.001 and r=0.47, p=0.01, respectively). In the entire cohort of ex-smokers, cutaneous elastin degradation was associated with emphysema severity, FEV<SUB>1</SUB> and pulse wave velocity.</p></sec><sec><st>Conclusions</st><p>Patients with COPD have increased skin elastin degradation compared with controls, which is related to emphysema severity and arterial stiffness. Systemic elastin degradation due to increased proteolytic activity may represent a novel shared mechanism for the pulmonary, vascular and cutaneous features of COPD.</p></sec>]]></description>
<dc:creator><![CDATA[Maclay, J. D., McAllister, D. A., Rabinovich, R., Haq, I., Maxwell, S., Hartland, S., Connell, M., Murchison, J. T., van Beek, E. J. R., Gray, R. D., Mills, N. L., MacNee, W.]]></dc:creator>
<dc:date>2012-02-28T02:05:07-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200949</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200949</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Radiology (diagnostics), Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Systemic elastin degradation in chronic obstructive pulmonary disease]]></dc:title>
<prism:publicationDate>2012-02-28</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200279v2?rss=1">
<title><![CDATA[Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200279v2?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Although an increased concentration of degraded elastin products in patients with chronic obstructive pulmonary disease (COPD) has been reported for many years, its clinical validity and utility remain uncertain due to technical difficulties, small study groups and the unknown relationship between exacerbation and elastin degradation. The objectives of this study were to determine the validity of urinary and blood total desmosine/isodesmosine in patients with COPD and asthma and to evaluate their relationship to exacerbation status and lung function.</p></sec><sec><st>Methods</st><p>Urinary and blood desmosine levels were measured using validated isotopic dilution liquid chromatography&ndash;tandem mass spectrometry methods.</p></sec><sec><st>Results</st><p>390 study participants were recruited from the following groups: healthy volunteers, stable asthma, stable and &lsquo;during an exacerbation&rsquo; COPD. Compared with healthy non-smokers, we found increased urinary or blood desmosine levels in patients with COPD, but no differences in patients with asthma or healthy smokers. The elevation of urinary desmosine levels was associated with the exacerbation status in patients with COPD. Approximately 40% of patients with stable and &lsquo;during an exacerbation&rsquo; COPD showed elevated blood desmosine levels. Blood desmosine levels were strongly associated with age and were negatively correlated with lung diffusing capacity for carbon monoxide.</p></sec><sec><st>Conclusion</st><p>The results suggest that urinary desmosine levels are raised by exacerbations of COPD whereas blood desmosine levels are elevated in a subgroup of patients with stable COPD and reduced lung diffusing capacity. The authors speculate that a raised blood desmosine level may identify patients with increased elastin degradation suitable for targeted therapy. Future prospective studies are required to investigate this hypothesis.</p></sec>]]></description>
<dc:creator><![CDATA[Huang, J. T.-J., Chaudhuri, R., Albarbarawi, O., Barton, A., Grierson, C., Rauchhaus, P., Weir, C. J., Messow, M., Stevens, N., McSharry, C., Feuerstein, G., Mukhopadhyay, S., Brady, J., Palmer, C. N. A., Miller, D., Thomson, N. C.]]></dc:creator>
<dc:date>2012-02-22T02:01:23-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200279</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200279</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Asthma, Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease]]></dc:title>
<prism:publicationDate>2012-02-22</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201666v1?rss=1">
<title><![CDATA[Allergic rhinitis and asthma require an integrated management]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201666v1?rss=1</link>
<description><![CDATA[<p>We read with interest and congratulate the authors de Groot <I>et al</I> for the article on the impact of comorbid allergic rhinitis (AR) on asthma control in children.<cross-ref type="bib" refid="b1">1</cross-ref> We entirely agree with de Groot and coworkers that despite its high prevalence, surprisingly there are few studies on the effects of treatment of AR in asthmatic children and adolescents.</p><p>Considering its high frequency and association with poor control of asthma, among untreated and even treated subjects,<cross-ref type="bib" refid="b2">2</cross-ref> it is noteworthy that in low&ndash;middle income countries, affordability and availability of both inhaled and intranasal corticosteroids is a well-recognised problem. Driven by these circumstances, we assessed the efficacy of exclusive nasal inhalation for the concomitant treatment of asthma and rhinitis in three randomised controlled trials, one of them<cross-ref type="bib" refid="b3">3</cross-ref> cited in the paper by de Groot <I>et al</I>.<cross-ref type="bib" refid="b1">1</cross-ref></p><p>In their paper, however, de Groot <I>et al</I> stated that &lsquo;One...]]></description>
<dc:creator><![CDATA[Camargos, P., Ibiapina, C., Lasmar, L., Cruz, A. A.]]></dc:creator>
<dc:date>2012-02-21T02:01:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201666</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201666</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Allergic rhinitis and asthma require an integrated management]]></dc:title>
<prism:publicationDate>2012-02-21</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201308v1?rss=1">
<title><![CDATA[Necrotising pneumonia, pneumatoceles and the pneumococcus]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201308v1?rss=1</link>
<description><![CDATA[<p>We commend Principi and Esposito for their timely review of severe community-acquired pneumonia in children.<cross-ref type="bib" refid="b1">1</cross-ref> They state that the leading cause of necrotising pneumonia and pneumatoceles within the context of community acquired pneumonia is <I>Staphylococcus aureus</I>. We must disagree with this claim.</p><p>Historically, <I>S aureus</I> has been the principal organism associated with necrotic or cavitary pneumonia in children, but recent data demonstrate <I>Streptococcus pneumoniae</I> is now a much more important cause.<cross-ref type="bib" refid="b2">2&ndash;4</cross-ref><cross-ref type="bib" refid="b3"></cross-ref><cross-ref type="bib" refid="b4"></cross-ref> Pneumococcal infection was the leading cause of necrotic or cavitary pneumonia in two recent studies by Sawicki <I>et al</I> in Boston and Mckee <I>et al</I> in London, accounting for 89% (28/32) of cases in the latter<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref>; this figure will underestimate the true incidence of pneumococcal infection as over 90% of invasive pneumococcal disease is culture negative, and culture negative techniques for determining pneumococcal infection and serotype are...]]></description>
<dc:creator><![CDATA[Thomas, M. F., Spencer, D. A.]]></dc:creator>
<dc:date>2012-02-16T02:01:22-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201308</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201308</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Necrotising pneumonia, pneumatoceles and the pneumococcus]]></dc:title>
<prism:publicationDate>2012-02-16</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201582v1?rss=1">
<title><![CDATA[Inequalities in outcomes for non-small cell lung cancer: the role of the MDT]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201582v1?rss=1</link>
<description><![CDATA[<p>Rich <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> report that non-small cell lung cancer patients first seen in a hospital which has on-site thoracic surgical services are more likely to have surgical treatment of their tumour. However, it is not clear what aspects of &lsquo;being a surgical centre&rsquo; are crucial to increasing resection rates. Numerous reports have documented a volume&ndash;outcome relationship for complex surgical and medical care and one hypothesis to explain this relationship is higher case load since surgical units tend to be located in large hospitals serving large populations.</p><p>To assess this, we analysed all 129 052 cases submitted to the NLCA (England only) between 2006 and 2010 inclusive, based on the &lsquo;place first seen&rsquo; as a surrogate marker of the decision-making multidisciplinary team (MDT). After excluding cases with &lsquo;negative survival&rsquo;, no recorded place first seen and trusts with &lt;100 cases over the 5-year time span, we divided the MDTs into quintiles based...]]></description>
<dc:creator><![CDATA[Beckett, P., Woolhouse, I.]]></dc:creator>
<dc:date>2012-02-14T02:03:35-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201582</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201582</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Inequalities in outcomes for non-small cell lung cancer: the role of the MDT]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201249v1?rss=1">
<title><![CDATA[Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201249v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Although women with severe non-allergic asthma may represent a substantial proportion of adults with asthma in clinical practice, gender differences in the incidence of allergic and non-allergic asthma have been little investigated in the general population.</p></sec><sec><st>Methods</st><p>Gender differences in asthma prevalence, reported diagnosis and incidence were investigated in 9091 men and women randomly selected from the general population and followed up after 8&ndash;10&nbsp;years as part of the European Community Respiratory Health Survey. The protocol included assessment of bronchial responsiveness, IgE specific to four common allergens and skin tests to nine allergens.</p></sec><sec><st>Results</st><p>Asthma was 20% more frequent in women than in men over the age of 35&nbsp;years. Possible under-diagnosis of asthma appeared to be particularly frequent among non-atopic individuals, but was as frequent in women as in men. The follow-up of subjects without asthma at baseline showed a higher incidence of asthma in women than in men (HR 1.94; 95% CI 1.40 to 2.68), which was not explained by differences in smoking, obesity or lung function. More than 60% of women and 30% of men with new-onset asthma were non-atopic. The incidence of non-allergic asthma was higher in women than in men throughout all the reproductive years (HR 3.51; 95% CI 2.21 to 5.58), whereas no gender difference was observed for the incidence of allergic asthma.</p></sec><sec><st>Conclusions</st><p>This study shows that female sex is an independent risk factor for non-allergic asthma, and stresses the need for more careful assessment of possible non-allergic asthma in clinical practice, in men and women.</p></sec>]]></description>
<dc:creator><![CDATA[Leynaert, B., Sunyer, J., Garcia-Esteban, R., Svanes, C., Jarvis, D., Cerveri, I., Dratva, J., Gislason, T., Heinrich, J., Janson, C., Kuenzli, N., de Marco, R., Omenaas, E., Raherison, C., Gomez Real, F., Wjst, M., Zemp, E., Zureik, M., Burney, P. G. J., Anto, J. M., Neukirch, F.]]></dc:creator>
<dc:date>2012-02-14T02:03:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201249</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201249</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Health policy, Epidemiologic studies, Asthma, Health service research, Health education, Obesity (public health), Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Epidemiology</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200651v1?rss=1">
<title><![CDATA[1{alpha},25-Dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200651v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>CD200, a cell-surface immunoglobulin-like molecule expressed by immune and stromal cells, dampens the pro-inflammatory activity of tissue-resident innate cells via its receptor, CD200R. This interaction appears critical for peripheral immune tolerance, particularly in the airways where excessive inflammation is undesirable. Vitamin D contributes to pulmonary health and promotes regulatory immune pathways, therefore its influence on CD200 and CD200R was investigated.</p></sec><sec><st>Methods</st><p>CD200 and CD200R expression were assessed by qPCR and immunoreactivity of human lymphoid, myeloid and epithelial cells following 1&alpha;,25-dihydroxyvitamin D3 (1&alpha;,25VitD3) exposure in vitro and in peripheral T cells following 1&alpha;,25VitD3 oral ingestion in vivo. The effect of 1&alpha;25VitD3 was also assessed in human airway-resident cells.</p></sec><sec><st>Results</st><p>1&alpha;25VitD3 potently upregulated CD200 on peripheral human CD4+ T cells in vitro, and in vivo there was a trend towards upregulation in healthy, but not asthmatic individuals. CD200R expression was not modulated in any cells studied. CD200 induction was observed to a lesser extent in CD8+ T cells and not in B cells or airway epithelium. T cells isolated from the human airway also responded strongly to 1&alpha;25VitD3 to upregulate CD200.</p></sec><sec><st>Conclusions</st><p>The capacity of 1&alpha;,25-dihydroxyvitamin D3 to induce CD200 expression by peripheral and respiratory tract T cells identifies an additional pathway via which vitamin D can restrain inflammation in the airways to maintain respiratory health.</p></sec>]]></description>
<dc:creator><![CDATA[Dimeloe, S., Richards, D. F., Urry, Z. L., Gupta, A., Stratigou, V., Farooque, S., Saglani, S., Bush, A., Hawrylowicz, C. M.]]></dc:creator>
<dc:date>2012-02-14T02:03:36-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200651</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200651</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Inflammation, Asthma]]></dc:subject>
<dc:title><![CDATA[1{alpha},25-Dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Airway biology</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201409v1?rss=1">
<title><![CDATA['White out': a rare cause]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201409v1?rss=1</link>
<description><![CDATA[<p>A patient in their mid-40s presented with a history of worsening dyspnoea. The patient had neurofibromatosis type 1 and had previous spinal surgery for kyphoscoliosis.</p><p>A chest x-ray showed a right sided &lsquo;white out&rsquo;, thought to be a pleural effusion (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). CT thorax showed a thoracic scoliosis with internal fixation and a large fluid collection within the right hemithorax. A chest drain was scheduled to be inserted.</p><p>However, further review of the CT images identified an unusual abnormality within the right hemithorax. Several of the thoracic spinal pedicles were absent and there was communication of fluid from a dilated spinal canal to the large fluid collection within the right hemithorax (<cross-ref type="fig" refid="fig1">figure 1B</cross-ref>).</p><p>A thoracic MR image confirmed the appearance was due to a large cerebrospinal fluid collection within the right hemithorax, which directly communicated to the right side of the spinal canal (<cross-ref type="fig" refid="fig1">figure 1C</cross-ref>). The appearances...]]></description>
<dc:creator><![CDATA[Tack, G., Ganeshan, D., Wide, J., Stockton, P.]]></dc:creator>
<dc:date>2012-02-14T02:03:35-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201409</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201409</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Journalology, Radiology (diagnostics), Ethics]]></dc:subject>
<dc:title><![CDATA['White out': a rare cause]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200874v1?rss=1">
<title><![CDATA[Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200874v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>Obstructive sleep apnoea (OSA) is associated with increased cardiovascular risk, however the mechanisms are not well established.</p></sec><sec><st>Objectives</st><p>This study aimed to determine whether treatment of OSA with nasal continuous positive airway pressure (CPAP) would favourably alter coagulability across the sleep&ndash;wake cycle.</p></sec><sec><st>Methods</st><p>In a randomised crossover trial, 28 patients received therapeutic or placebo CPAP, each for 2&nbsp;months with a 1&nbsp;month washout between treatments. After each treatment period, a 24&nbsp;h coagulation study was conducted in the laboratory. Plasminogen activator inhibitor-1 (PAI-1), D-dimer, fibrinogen, von Willebrand Factor (vWF), factor VIII (FVIII), factor VII (FVII) and factor V (FV) were determined at seven time points over the day and night.</p></sec><sec><st>Results</st><p>At baseline, patients had severe OSA (Apnoea Hypopnoea Index 37.9&plusmn;23.9&nbsp;events/h). Treatment of OSA with CPAP compared with placebo resulted in lower 24&nbsp;h levels of vWF (&ndash;3.9%, p=0.013), FVIII (&ndash;6.2%, p=0.007) and FV (&ndash;4.2%, p&lt;0.001). The greatest difference occurred during the nocturnal and early morning periods. In contrast, fibrinogen, D-dimer, FVII and PAI-1 did not differ between treatments, however all markers displayed diurnal variability independent of treatment.</p></sec><sec><st>Conclusions</st><p>In this randomised, placebo-controlled crossover trial, treatment of OSA with CPAP reduced the early morning level of vWF, and nocturnal levels of FVIII and FV. These findings suggest that CPAP may reduce cardiovascular risk in OSA, in part through reducing risk of thrombosis.</p></sec>]]></description>
<dc:creator><![CDATA[Phillips, C. L., McEwen, B. J., Morel-Kopp, M.-C., Yee, B. J., Sullivan, D. R., Ward, C. M., Tofler, G. H., Grunstein, R. R.]]></dc:creator>
<dc:date>2012-02-14T02:03:35-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200874</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200874</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Venous thromboembolism]]></dc:subject>
<dc:title><![CDATA[Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study]]></dc:title>
<prism:publicationDate>2012-02-14</prism:publicationDate>
<prism:section>Sleep disordered breathing</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201436v1?rss=1">
<title><![CDATA[Using lung cancer screening as an opportunity to diagnose COPD]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201436v1?rss=1</link>
<description><![CDATA[<p>Early diagnosis of chronic obstructive pulmonary disease (COPD) allows increased opportunity for smoking cessation advice and treatment, which potentially improves prognosis. This single-centre, prospective cross-sectional study investigated whether screening CT scans could diagnose COPD without the need for pulmonary function testing (PFT).</p><p>One thousand one hundred and forty men, ex or current smokers (&gt;16.5 pack year history), aged 50&ndash;75&nbsp;years, already enrolled in a lung cancer screening trial, had low dose screening inspiratory CT scans, PFT and an additional expiratory scan. Pre-bronchodilatory forced expiratory volume in one second/forced vital capacity ratio &lt;70% was used to diagnose COPD. Those with advanced disease, self-reported as unable to climb two flights stairs were excluded. CT emphysema, CT air trapping, body mass index, pack years and smoking status formed a diagnostic model to identify those with COPD.</p><p>Four hundred and thirty-seven (38%) subjects had COPD on PFT. The diagnostic model correctly diagnosed 274 patients with COPD, falsely...]]></description>
<dc:creator><![CDATA[Tinkler, M. L. S.]]></dc:creator>
<dc:date>2012-02-13T02:02:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201436</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201436</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Using lung cancer screening as an opportunity to diagnose COPD]]></dc:title>
<prism:publicationDate>2012-02-13</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201607v1?rss=1">
<title><![CDATA[Exposing children to secondhand smoke]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201607v1?rss=1</link>
<description><![CDATA[<p>In the October issue of <I>Thorax</I>, Leonardi-Bee <I>et al</I> reviewed the effects of parental smoking on the uptake of smoking by children.<cross-ref type="bib" refid="b1">1</cross-ref> They conclude that exposure to smoking within the family is a significant determinant of subsequent smoking.</p><p>One area that this study did not address was the effect of the site of the smoking on exposure.</p><p>We have studied urinary cotinine levels in children attending an asthma clinic and correlated them with the self-reported smoking habits of their carers. Thirty-six girls and 64 boys aged between 30 and 164&nbsp;months attending our asthma clinic were recruited if at least one carer smoked. The carers completed a questionnaire about their smoking habits and the child's urine was tested for cotinine using NicAlert, a commercially available reagent strip. Levels of 0&ndash;10&nbsp;ng/ml correspond to minimal or no nicotine exposure, 10&ndash;100&nbsp;ng/ml to moderate to high SHS exposure and &gt;100&nbsp;ng/ml to active smoking. Ten further...]]></description>
<dc:creator><![CDATA[Pool, J., Petrova, N., Russell, R. R.]]></dc:creator>
<dc:date>2012-02-10T02:09:25-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201607</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201607</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Exposing children to secondhand smoke]]></dc:title>
<prism:publicationDate>2012-02-10</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201669v1?rss=1">
<title><![CDATA[CPAP may reduce cardiovascular mortality in patients with OSA]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201669v1?rss=1</link>
<description><![CDATA[<p>This double-blind randomised crossover study of patients with moderate-to-severe obstructive sleep apnoea (OSA) compared 3&nbsp;months of therapeutic continuous positive airway pressure (CPAP) with 3&nbsp;months of sham CPAP with a 1&nbsp;month wash-out period in between. Markers of the metabolic syndrome were measured before and after each CPAP treatment.</p><p>The study population comprised 86 CPAP na&iuml;ve patients aged 30&ndash;65 who were recruited from a sleep laboratory in New Delhi, India. Exclusion criteria were previous or current treatment for hypertension, diabetes, dyslipidemia or any evidence of end-organ damage due to these conditions.</p><p>There were modest, statistically significant, reductions in systolic and diastolic blood pressure, glycated haemoglobin, triglycerides, low-density lipoprotein, non-high-density lipoprotein and total cholesterol after CPAP therapy as compared with sham therapy. Additionally, there were significant decreases in body mass index and visceral and subcutaneous fat. Carotid intimal thickness and insulin resistance did not differ significantly. Applying the authors' criteria for the metabolic syndrome, there...]]></description>
<dc:creator><![CDATA[Reynolds, C. J.]]></dc:creator>
<dc:date>2012-02-10T02:03:28-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201669</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201669</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[CPAP may reduce cardiovascular mortality in patients with OSA]]></dc:title>
<prism:publicationDate>2012-02-10</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201586v1?rss=1">
<title><![CDATA[Chronic disease management for tobacco dependence]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201586v1?rss=1</link>
<description><![CDATA[<p>This randomised control trial compared the efficacy of utilising chronic disease management principles for tobacco dependence using a tailored intervention with standard care. As tobacco dependence is a chronic relapsing condition, the tailored intervention was chosen to account for possible interim setbacks.</p><p>Four hundred and forty-three eligible participants received five telephone-counselling calls and 4&nbsp;weeks of nicotine replacement therapy. They were randomised to receive continuing counselling and nicotine replacement therapy for 1&nbsp;year (longitudinal care, LC) or to receive one additional call at 8&nbsp;weeks (evidence-based usual care, UC). The primary outcome was 6&nbsp;months of prolonged abstinence, measured at 18&nbsp;months following initial quit date. Secondary outcomes included abstinence rates before 6&nbsp;months and smoking reduction.</p><p>At 18&nbsp;months, 30.2% of LC participants reported 6&nbsp;months of abstinence from smoking, compared with 23.5% in UC. Prior to 6&nbsp;months, abstinence rates were slightly higher with UC than LC. At all time points, those who did not quit had greater smoking...]]></description>
<dc:creator><![CDATA[Chandrasekera, H. M.]]></dc:creator>
<dc:date>2012-01-27T04:01:39-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201586</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201586</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Chronic disease management for tobacco dependence]]></dc:title>
<prism:publicationDate>2012-01-27</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200424v1?rss=1">
<title><![CDATA[Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450 patients]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200424v1?rss=1</link>
<description><![CDATA[<sec><st>Introduction</st><p>The value of pleural lavage cytology (PLC) in assessing the prognosis of early stage lung cancer is still controversial. No systematic review has investigated the relationship between PLC and lung cancer recurrence. Our primary goal was to investigate the association between positive pre-resection PLC and pleural, distant and overall tumour recurrence in patients undergoing surgical resection.</p></sec><sec><st>Methods</st><p>Medline, EMBASE and Google Scholar databases were searched up to 2011. All studies reporting relevant outcomes in both patient groups were included. Data were extracted for the following outcomes of interest: overall, local and distant recurrence; and freedom from death (survival&mdash;overall and patients with stage I disease only). Random effects meta-analysis was used to aggregate the data. Sensitivity and heterogeneity analysis were performed.</p></sec><sec><st>Results</st><p>A meta-analysis of eight studies at maximum follow-up demonstrated a significant association between positive pre-resection PLC and increased risk of post-resection overall recurrence (OR 4.82, 95% CI 2.45 to 9.51), pleural recurrence (OR 9.89, 95% CI 5.95 to 16.44) and distant cancer recurrence (OR 3.18, 95% CI 1.57 to 6.46). Furthermore, a meta-analysis of 17 studies suggested that positive pre-resection PLC was also associated with unfavourable survival (HR 2.08, 95% CI 1.71 to 2.52). These findings were supported by sensitivity analysis.</p></sec><sec><st>Discussion</st><p>Positive pre-resection PLC is associated with higher overall, distant and local tumour recurrence and unfavourable patient survival outcomes. This technique may therefore act as a predictor of tumour recurrence and adverse survival. Furthermore, its role in including adjuvant chemotherapy to the management protocol should be investigated within randomised controlled trials.</p></sec>]]></description>
<dc:creator><![CDATA[Saso, S., Rao, C., Ashrafian, H., Ghaem-Maghami, S., Darzi, A., Athanasiou, T.]]></dc:creator>
<dc:date>2012-01-27T04:01:40-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200424</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200424</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung neoplasms, Clinical trials (epidemiology), Vaccination / immunisation, Lung cancer (oncology), Lung cancer (respiratory medicine), Internet]]></dc:subject>
<dc:title><![CDATA[Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450 patients]]></dc:title>
<prism:publicationDate>2012-01-27</prism:publicationDate>
<prism:section>Lung cancer</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200864v1?rss=1">
<title><![CDATA[Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200864v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Collateral ventilation has been proposed as a mechanism of compensation of respiratory function in obstructive lung diseases but observations of it in vivo are limited. The assessment of collateral ventilation with an imaging technique might help to gain insight into lung physiology and assist the planning of new bronchoscopic techniques for treating emphysema.</p></sec><sec><st>Objective</st><p>To obtain images of delayed ventilation that might be related to collateral ventilation over the period of a single breath-hold in patients with chronic obstructive pulmonary disease (COPD).</p></sec><sec><st>Methods</st><p>Time-resolved breath-hold hyperpolarised <sup>3</sup>He MRI was used to obtain images of the progressive influx of polarised gas into initially non-ventilated defects.</p></sec><sec><st>Results</st><p>A time-series of images showed that <sup>3</sup>He moves into lung regions which were initially non-ventilated. Ventilation defects with delayed filling were observed in 8 of the 10 patients scanned.</p></sec><sec><st>Conclusions</st><p>A method for direct imaging of delayed ventilation within a single breath-hold has been demonstrated in patients with COPD. Images of what is believed to be collateral ventilation and slow filling of peripheral airspaces due to increased flow resistance are presented. The technique provides 3D whole-lung coverage with sensitivity to regional information, and is non-invasive and non-ionising.</p></sec>]]></description>
<dc:creator><![CDATA[Marshall, H., Deppe, M. H., Parra-Robles, J., Hillis, S., Billings, C. G., Rajaram, S., Swift, A., Miller, S. R., Watson, J. H., Wolber, J., Lipson, D. A., Lawson, R., Wild, J. M.]]></dc:creator>
<dc:date>2012-01-27T04:01:39-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200864</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200864</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Cardiothoracic surgery]]></dc:subject>
<dc:title><![CDATA[Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI]]></dc:title>
<prism:publicationDate>2012-01-27</prism:publicationDate>
<prism:section>Chronic obstructive pulmonary disease</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201422v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201422v1?rss=1</link>
<description><![CDATA[<p>In their letter,<cross-ref type="bib" refid="b1">1</cross-ref> Mastrangelo and colleagues argue that our analyses on occupational organic dust exposure and its specific constituents (eg, endotoxin) suffered from inadequacies that hampered their interpretation. They argue that, given that the effect of endotoxin might diminish after cessation of exposure, analyses of ever versus never exposed to endotoxin might fail to identify the protective effect of endotoxin. Furthermore, they argue that the failure to differentiate between livestock/dairy and crop/orchard farmers may have obscured the protective effect as some papers have argued that the effect is contained (largely) to livestock/dairy farmers only.</p><p>The main aim of our paper was to study the association between occupational exposure to organic dust and its constituents and lung cancer in the general population. For cumulative exposure to organic dust we observed a significantly increased risk of lung cancer. No associations were found between cumulative exposure to endotoxin and lung cancer. Exposures...]]></description>
<dc:creator><![CDATA[Peters, S., Kromhout, H., Olsson, A., Straif, K., Vermeulen, R., on behalf of all authors]]></dc:creator>
<dc:date>2012-01-26T20:43:22-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201422</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201422</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2012-01-26</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201587v1?rss=1">
<title><![CDATA[Management of latent tuberculosis infection]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2012-201587v1?rss=1</link>
<description><![CDATA[<p>Treatment for latent tuberculosis has the potential to significantly reduce the incidence of active tuberculosis infection, but patient adherence to treatment regimens is often limited by the lengthy duration of treatment required. This study evaluated the efficacy of a 3-month regimen of rifapentine plus isoniazid administered as directly observed once-weekly therapy compared with 9&nbsp;months daily self-administered isoniazid.</p><p>The investigators carried out an open-label non-inferiority trial in which 3986 subjects were randomised to combination therapy and 3745 randomised to isoniazid monotherapy. Subjects were enrolled if they had a positive tuberculin skin test or were a close contact of a patient with tuberculosis. Contacts of patients with drug-resistant tuberculosis were excluded. Subjects were followed-up for 33&nbsp;months from enrolment and the primary end point evaluated was the development of active tuberculosis in the study subjects.</p><p>The study demonstrated that 3&nbsp;months directly observed weekly combination therapy is non-inferior to 9&nbsp;months daily self-administered isoniazid. Seven patients developed...]]></description>
<dc:creator><![CDATA[Brown, J.]]></dc:creator>
<dc:date>2012-01-23T06:00:14-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2012-201587</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2012-201587</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Management of latent tuberculosis infection]]></dc:title>
<prism:publicationDate>2012-01-23</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201176v1?rss=1">
<title><![CDATA[Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201176v1?rss=1</link>
<description><![CDATA[<sec><st>Rationale</st><p>Bacterial pneumonia is the most common infectious cause of death worldwide and treatment is increasingly hampered by antibiotic resistance. Mesenchymal stem cells (MSCs) have been demonstrated to provide protection against acute inflammatory lung injury; however, their potential therapeutic role in the setting of bacterial pneumonia has not been well studied.</p></sec><sec><st>Objective</st><p>This study focused on testing the therapeutic and mechanistic effects of MSCs in a mouse model of Gram-negative pneumonia.</p></sec><sec><st>Methods and results</st><p>Syngeneic MSCs from wild-type mice were isolated and administered via the intratracheal route to mice 4&nbsp;h after the mice were infected with <I>Escherichia coli</I>. 3T3 fibroblasts and phosphate-buffered saline (PBS) were used as controls for all in vivo experiments. Survival, lung injury, bacterial counts and indices of inflammation were measured in each treatment group. Treatment with wild-type MSCs improved 48&nbsp;h survival (MSC, 55%; 3T3, 8%; PBS, 0%; p&lt;0.05 for MSC vs 3T3 and PBS groups) and lung injury compared with control mice. In addition, wild-type MSCs enhanced bacterial clearance from the alveolar space as early as 4&nbsp;h after administration, an effect that was not observed with the other treatment groups. The antibacterial effect with MSCs was due, in part, to their upregulation of the antibacterial protein lipocalin 2.</p></sec><sec><st>Conclusions</st><p>Treatment with MSCs enhanced survival and bacterial clearance in a mouse model of Gram-negative pneumonia. The bacterial clearance effect was due, in part, to the upregulation of lipocalin 2 production by MSCs.</p></sec>]]></description>
<dc:creator><![CDATA[Gupta, N., Krasnodembskaya, A., Kapetanaki, M., Mouded, M., Tan, X., Serikov, V., Matthay, M. A.]]></dc:creator>
<dc:date>2012-01-16T07:53:48-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201176</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201176</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Drugs: infectious diseases, Pneumonia (infectious disease), TB and other respiratory infections, Inflammation, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia]]></dc:title>
<prism:publicationDate>2012-01-16</prism:publicationDate>
<prism:section>Respiratory infection</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200829v1?rss=1">
<title><![CDATA[A puzzling tumour]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200829v1?rss=1</link>
<description><![CDATA[<sec><st>Case</st><p>A 58-year-old never-smoker man developed dyspnoea, cough, fevers, weight loss and tremulousness over 4&nbsp;weeks. He had a brief history of asbestos exposure. Significant medical history included autosomal-dominant polycycstic kidney disease (APKD) and renal transplantation 7&nbsp;years previously. He took mycophenolate mofetil and tacrolimus immune-suppressants. Examination revealed tachypnoea, a fine right arm tremor, bronchial breathing on the right and a superficial 1<FONT FACE="arial,helvetica">x</FONT>2&nbsp;cm non-fluctuant lump over the abdomen. Lymph nodes were impalpable.</p><p>Screening blood tests showed values of c reactive protein 115&nbsp;mg/l (NR &lt;6.0), urea 25.8&nbsp;mmol/l, creatinine 254&nbsp;umol/l (post-transplant baseline 220&ndash;230) and tacrolimus 25.5<FONT FACE="arial,helvetica">x</FONT>&micro;g/l (NR 5&ndash;10). Autoimmune profile was negative. PCR detected cytomegalovirus (CMV) levels at 31 338 copies/ml. Plain chest radiography showed right upper lobe consolidation (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). An abdominal ultrasound scan revealed a normal transplanted kidney. Intravenous empirical antibiotics and oral valganciclovir, subsequently changed to intravenous ganciclovir, were administered.</p><p>The clinical response was slow. CT thoraco-abdominal scans noted a right upper lobe...]]></description>
<dc:creator><![CDATA[Kamara, A., Dubrey, S., Osman, M., Mikel, J., Phillips, G.]]></dc:creator>
<dc:date>2012-01-16T07:53:48-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200829</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200829</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Drugs: infectious diseases, Neuromuscular disease, Respiratory cancer, Screening (oncology), Inflammation, Venous thromboembolism, Asthma, Pulmonary embolism, Cardiothoracic surgery, Transplantation, Screening (epidemiology), Occupational and environmental medicine, Environmental issues, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[A puzzling tumour]]></dc:title>
<prism:publicationDate>2012-01-16</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201453v1?rss=1">
<title><![CDATA[Increasing smokers' risk perception improves CT screening participation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201453v1?rss=1</link>
<description><![CDATA[<p>We read with interest the article by Patel <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> and wish to comment on their findings with specific regard to smokers' risk perception, motivation and low participation rates in CT screening programmes.</p><p>Based on the studies to date, there is a consistent theme that smokers' participation in CT screening programmes for lung cancer is poor when their motivation is low and much greater when their perception of risk of lung cancer is high.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> Despite overwhelming public health messaging, smokers continue to smoke, in large part, because they perceive their own risk from smoking to be low. This self-perception of low risk (termed optimistic bias) maintains a low level of motivational tension (the fear that smoking might indeed be harmful).<cross-ref type="bib" refid="b3">3</cross-ref> We propose that optimistic bias can be undermined, and motivational tension increased, when smokers are confronted with adverse &lsquo;personalised&rsquo; risk data.<cross-ref type="bib"...]]></description>
<dc:creator><![CDATA[Young, R. P., Hopkins, R. J.]]></dc:creator>
<dc:date>2012-01-16T07:53:46-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201453</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201453</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Increasing smokers' risk perception improves CT screening participation]]></dc:title>
<prism:publicationDate>2012-01-16</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201279v1?rss=1">
<title><![CDATA[Lung cancer risk in subjects exposed to organic dust: an unexpected and surprising story]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201279v1?rss=1</link>
<description><![CDATA[<p>In a recently published multicentre case&ndash;control study evaluating lung cancer risk among subjects exposed to organic dusts,<cross-ref type="bib" refid="b1">1</cross-ref> the authors could not confirm the findings from previous reports in which a decreased risk was found among workers in the cotton industry and animal farmers.<cross-ref type="bib" refid="b2">2</cross-ref></p><p>Regarding a decreased risk of lung cancer among cotton workers<cross-ref type="bib" refid="b3">3&ndash;7</cross-ref><cross-ref type="bib" refid="b4"></cross-ref><cross-ref type="bib" refid="b5"></cross-ref><cross-ref type="bib" refid="b6"></cross-ref><cross-ref type="bib" refid="b7"></cross-ref> the authors quite rightly concluded that their material was not suitable to evaluate this relationship as their subgroups did not reflect the critical exposure groups, i.e. those exposed to high levels of endotoxin such as cardroom workers and weavers.<cross-ref type="bib" refid="b8">8</cross-ref></p><p>For farmers we believe that the multicentre case&ndash;control study findings have the same shortcomings for the following reasons. In the Veneto region of Italy, where the first study reporting a decreased risk of lung cancer among farmers was carried out,<cross-ref type="bib" refid="b9">9</cross-ref> the number...]]></description>
<dc:creator><![CDATA[Mastrangelo, G., Rylander, R., Cegolon, L., Lange, J.]]></dc:creator>
<dc:date>2012-01-10T17:57:06-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201279</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201279</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Lung cancer risk in subjects exposed to organic dust: an unexpected and surprising story]]></dc:title>
<prism:publicationDate>2012-01-10</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201168v1?rss=1">
<title><![CDATA[Allergic rhinitis is associated with poor asthma control in children with asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201168v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Asthma and allergic rhinitis are the two most common chronic disorders in childhood and adolescence. To date, no study has examined the impact of comorbid allergic rhinitis on asthma control in children.</p></sec><sec><st>Objective</st><p>To examine the prevalence of allergic rhinitis in children with asthma, and the impact of the disease and its treatment on asthma control.</p></sec><sec><st>Methods</st><p>A cross-sectional survey in 203 children with asthma (5&ndash;18&nbsp;years) using validated questionnaires on rhinitis symptoms (stuffy or runny nose outside a cold) and its treatment, and the paediatric Asthma Control Questionnaire (ACQ). Fraction of nitric oxide in exhaled air (FeNO) was measured with a Niox Mino analyser; total and specific IgE levels were assessed by the Immunocap system.</p></sec><sec><st>Results</st><p>157 children (76.2%) had symptoms of allergic rhinitis but only 88 of these (56.1%) had been diagnosed with the condition by a physician. ACQ scores were worse in children with allergic rhinitis than in those without the condition (p=0.012). An ACQ score &ge;1.0 (incomplete asthma control) was significantly more likely in children with allergic rhinitis than in those without (OR 2.74, 95% CI 1.28 to 5.91, p=0.0081), also after adjustment for FeNO levels and total serum IgE. After adjustment for nasal corticosteroid therapy, allergic rhinitis was no longer associated with incomplete asthma control (OR 0.72, 95% CI 0.47 to 1.12, p=0.150).</p></sec><sec><st>Conclusion</st><p>Allergic rhinitis is common in children with asthma, and has a major impact on asthma control. The authors hypothesise that recognition and treatment of this condition with nasal corticosteroids may improve asthma control in children, but randomised clinical trials are needed to test this hypothesis.</p></sec>]]></description>
<dc:creator><![CDATA[de Groot, E. P., Nijkamp, A., Duiverman, E. J., Brand, P. L. P.]]></dc:creator>
<dc:date>2012-01-02T11:33:02-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201168</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201168</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[TB and other respiratory infections, Child health, Asthma, Ear, nose and throat/otolaryngology]]></dc:subject>
<dc:title><![CDATA[Allergic rhinitis is associated with poor asthma control in children with asthma]]></dc:title>
<prism:publicationDate>2012-01-02</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200405v1?rss=1">
<title><![CDATA[Impaired type I and type III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200405v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Rhinoviruses are important triggers of pulmonary exacerbations and possible contributors to long-term respiratory morbidity in cystic fibrosis (CF), but mechanisms leading to rhinovirus-induced CF exacerbations are poorly understood. It is hypothesised that there is a deficient innate immune response of the airway epithelium towards rhinovirus infection in CF.</p></sec><sec><st>Methods</st><p>Early innate immune responses towards rhinoviruses (RV-16, major-type and RV-1B, minor-type) in CF and non-CF bronchial epithelial cell lines and primary nasal and bronchial epithelial cells from patients with CF (n=13) and healthy controls (n=24) were studied.</p></sec><sec><st>Results</st><p>Rhinovirus RNA expression and virus release into supernatants was increased more than tenfold in CF cells compared with controls. CF cells expressed up to 1000 times less interferon (IFN) type I (&beta;) and type III () mRNA and produced less than half of IFN-&beta; and IFN- protein compared with controls. In contrast, interleukin 8 production was not impaired, indicating a selective deficiency in the innate antiviral defence system. Deficient IFN production was paralleled by lower expression of IFN-stimulated genes including myxovirus resistance A, 2',5'-oligoadenylate synthetase, viperin and nitric oxide synthase 2. Addition of exogenous type I and III IFNs, particularly IFN-&beta;, restored antiviral pathways and virus control in CF cells, underscoring the crucial role of these molecules.</p></sec><sec><st>Conclusions</st><p>This study describes a novel mechanism to explain the increased susceptibility of patients with CF to rhinovirus infections. A profound impairment of the antiviral early innate response in CF airway epithelial cells was identified, suggesting a potential use of IFNs in the treatment of rhinovirus-induced CF exacerbations.</p></sec>]]></description>
<dc:creator><![CDATA[Vareille, M., Kieninger, E., Alves, M. P., Kopf, B. S., Moller, A., Geiser, T., Johnston, S. L., Edwards, M. R., Regamey, N.]]></dc:creator>
<dc:date>2012-01-02T11:33:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200405</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200405</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: infectious diseases, TB and other respiratory infections, Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Impaired type I and type III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells]]></dc:title>
<prism:publicationDate>2012-01-02</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200912v1?rss=1">
<title><![CDATA[Progression of early structural lung disease in young children with cystic fibrosis assessed using CT]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200912v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Cross-sectional studies implicate neutrophilic inflammation and pulmonary infection as risk factors for early structural lung disease in infants and young children with cystic fibrosis (CF). However, the longitudinal progression in a newborn screened population has not been investigated.</p></sec><sec><st>Aim</st><p>To determine whether early CF structural lung disease persists and progresses over 1&nbsp;year and to identify factors associated with radiological persistence and progression.</p></sec><sec><st>Methods</st><p>143 children aged 0.2&ndash;6.5&nbsp;years with CF from a newborn screened population contributed 444 limited slice annual chest CT scans for analysis that were scored for bronchiectasis and air trapping and analysed as paired scans 1&nbsp;year apart. Logistic and linear regression models, using generalised estimating equations to account for multiple measures, determined associations between persistence and progression over 1&nbsp;year and age, sex, severe cystic fibrosis transmembrane regulator (CFTR) genotype, pancreatic sufficiency, current respiratory symptoms, and neutrophilic inflammation and infection measured by bronchoalveolar lavage.</p></sec><sec><st>Results</st><p>Once detected, bronchiectasis persisted in 98/133 paired scans (74%) and air trapping in 178/220 (81%). The extent of bronchiectasis increased in 139/227 (63%) of paired scans and air trapping in 121/264 (47%). Radiological progression of bronchiectasis and air trapping was associated with severe CFTR genotype, worsening neutrophilic inflammation and pulmonary infection.</p></sec><sec><st>Discussion</st><p>CT-detected structural lung disease identified in infants and young children with CF persists and progresses over 1&nbsp;year in most cases, with deteriorating structural lung disease associated with worsening inflammation and pulmonary infection. Early intervention is required to prevent or arrest the progression of structural lung disease in young children with CF.</p></sec>]]></description>
<dc:creator><![CDATA[Mott, L. S., Park, J., Murray, C. P., Gangell, C. L., de Klerk, N. H., Robinson, P. J., Robertson, C. F., Ranganathan, S. C., Sly, P. D., Stick, S. M., on behalf of AREST CF]]></dc:creator>
<dc:date>2011-12-26T07:25:52-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200912</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200912</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung infection, Epidemiologic studies, TB and other respiratory infections, Inflammation, Cystic fibrosis]]></dc:subject>
<dc:title><![CDATA[Progression of early structural lung disease in young children with cystic fibrosis assessed using CT]]></dc:title>
<prism:publicationDate>2011-12-26</prism:publicationDate>
<prism:section>Cystic fibrosis</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201383v1?rss=1">
<title><![CDATA[Hyperoxia in acute asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201383v1?rss=1</link>
<description><![CDATA[<p>We read with interest the recent article &lsquo;Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma&rsquo; by Perrin <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> and the accompanying editorial. We note that data presented in the online supplement suggest, unsurprisingly, response to treatment at 60&nbsp;min in terms of respiratory rate and forced expiratory volume in one second, probably explaining the rise in transcutaneous partial pressure of carbon dioxide (PtCO<SUB>2</SUB>) in this population. Therefore, it cannot be assumed that the PtCO<SUB>2</SUB> levels would have continued to rise after 60&nbsp;min as the authors suggest.</p><p>We are unconvinced by the implication that the levels of normocarbia and hypercarbia (up to 50&nbsp;mm&nbsp;Hg) demonstrated in this study are deleterious in acute asthma. Life-threatening respiratory failure in asthma is multifactorial, with ventilation&ndash;perfusion mismatch, lung hyperinflation and an increased work of breathing leading to respiratory muscle fatigue all being contributory factors.<cross-ref type="bib" refid="b2">2</cross-ref> A degree...]]></description>
<dc:creator><![CDATA[Snelson, C., Tunnicliffe, B.]]></dc:creator>
<dc:date>2011-12-20T16:49:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201383</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201383</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Hyperoxia in acute asthma]]></dc:title>
<prism:publicationDate>2011-12-20</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201418v1?rss=1">
<title><![CDATA[Physiotherapy interventions in the BTS guidelines on the management of asthma (2011): a need for change?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201418v1?rss=1</link>
<description><![CDATA[<p>Updates to the British Thoracic Society (BTS) asthma guidelines have been recently highlighted by Turner and colleagues.<cross-ref type="bib" refid="b1">1</cross-ref> <cross-ref type="bib" refid="b2">2</cross-ref> To our concern, the content on physiotherapy interventions has not been revised or updated since the 2006 version.</p><p>We reviewed the contents of the new BTS guidelines relevant for physiotherapists. The timescale for literature search indicates that the relevant section was last updated in February 2006, with coverage in Medline extending from 1996 to 2005.</p><p>Thus, we searched PubMed for English language papers published between January 2006 and December 2010 and found 32 indexed as randomised controlled trials. In the Cochrane Database of Systematic Reviews we found updates or revisions to all cited documents, with those updated in 2004 and 2005 and not quoted in the guideline.</p><p>A corresponding document, not referred to in the BTS guidelines, the joint BTS and the Association of Chartered Physiotherapists in Respiratory Care (ACPRC) Guidelines...]]></description>
<dc:creator><![CDATA[Nowobilski, R., Plaszewski, M., Wloch, T., Gajewski, P., Szczeklik, A.]]></dc:creator>
<dc:date>2011-12-18T23:55:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201418</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201418</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Physiotherapy interventions in the BTS guidelines on the management of asthma (2011): a need for change?]]></dc:title>
<prism:publicationDate>2011-12-18</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201438v1?rss=1">
<title><![CDATA[Mouse lung regeneration after H1N1]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201438v1?rss=1</link>
<description><![CDATA[<p>This study demonstrates that following an ARDS-like syndrome in mice secondary to infection with a murine-adapted H1N1 virus, complete recovery follows the emergence of a population of stem cells bearing the differentiation markers of alveoli.</p><p>Contrary to the existing bleomycin-based models of pulmonary injury causing fibrosis, this murine H1N1 model sustains substantial airway damage and epithelial destruction, followed by viral clearing and histological recovery over several months. This represents a novel paradigm to investigate regenerative responses to infection.</p><p>Using molecular and immunohistochemical methods, the authors illustrate that following H1N1 infection, a cell population expressing p63, a known marker of stem cells in nasal and tracheal epithelia, emerges from distal bronchial epithelia in damaged lung and expands to form discrete &lsquo;pods&rsquo; or islands of cells that concentrically surround distal airways. These pods assemble into novel alveoli-like structures bearing molecular markers and gene expression profiles of alveoli. Lineage tracing of these pods reveals a...]]></description>
<dc:creator><![CDATA[Mahmud, I.]]></dc:creator>
<dc:date>2011-12-18T23:55:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201438</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201438</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mouse lung regeneration after H1N1]]></dc:title>
<prism:publicationDate>2011-12-18</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201439v1?rss=1">
<title><![CDATA[Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201439v1?rss=1</link>
<description><![CDATA[<p>This randomised, multicentre, double-blind, placebo-controlled trial evaluated the efficacy and safety of four different doses of BIBF 1120, a tyrosine kinase inhibitor, in order to investigate its effect on progression of idiopathic pulmonary fibrosis (IPF).</p><p>The annual rate of decline in forced vital capacity (FVC), the primary end-point of this study, in the highest dose subgroup compared with the placebo subgroup failed to show statistical significance. However, the authors were able to demonstrate that the changes in FVC from baseline, total lung capacity, oxygen saturations, acute exacerbations and quality of life were statistically significantly better in the group receiving the highest dose of BIBF 1120. Serious adverse events were similar between groups, but lower in the highest dosing regimen compared with placebo. The most common reason for discontinuation of the medication was gastrointestinal upset.</p><p>Of note, only 33% of the patients recruited fulfilled the criteria for definite IPF with the remainder being...]]></description>
<dc:creator><![CDATA[Dawson, A. G.]]></dc:creator>
<dc:date>2011-12-14T15:06:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201439</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201439</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis]]></dc:title>
<prism:publicationDate>2011-12-14</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201437v1?rss=1">
<title><![CDATA[Endothelial cells as regulators of cytokine storms during influenza infection]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201437v1?rss=1</link>
<description><![CDATA[<p>The morbidity and mortality of severe influenza infections has been attributed to excessive inflammatory cytokine production and early innate immune cell recruitment. This study highlights the pulmonary endothelium as a central regulator of the cytokine storm, in particular demonstrating the role of the sphingosine-1-phosphate (S1P1) signalling system.</p><p>S1P1 receptor specific agonists were shown to significantly reduce cytokine responses and innate inflammation following infection of mice with mouse adapted influenza virus. Similar results were found using mice infected with a virulent isolate of the H1N1 pandemic influenza virus. S1P1 agonism also led to a reduction in mouse mortality.</p><p>Using an eGFP-S1P1 receptor knockin mouse and flow cytometry, high levels of S1P1 expression were detected in lung lymphatic and vascular endothelium, CD4 T cells and B cells. However, S1P1 agonist treatment of knockin mice did not alter the expression levels suggesting an effect through functional activation rather than receptor degradation. Furthermore, S1P1 treatment of...]]></description>
<dc:creator><![CDATA[Gautam, M.]]></dc:creator>
<dc:date>2011-12-14T15:06:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201437</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201437</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Endothelial cells as regulators of cytokine storms during influenza infection]]></dc:title>
<prism:publicationDate>2011-12-14</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200606v1?rss=1">
<title><![CDATA[The composition of house dust mite is critical for mucosal barrier dysfunction and allergic sensitisation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200606v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>House dust mite (HDM) allergens have been reported to increase airway epithelial permeability, thereby facilitating access of allergens and allergic sensitisation.</p></sec><sec><st>Objectives</st><p>The authors aimed to understand which biochemical properties of HDM are critical for epithelial immune and barrier responses as well as T helper 2-driven experimental asthma in vivo.</p></sec><sec><st>Methods</st><p>Three commercially available HDM extracts were analysed for endotoxin levels, protease and chitinase activities and effects on transepithelial resistance, junctional proteins and pro-inflammatory cytokine release in the bronchial epithelial cell line 16HBE and normal human bronchial cells. Furthermore, the effects on epithelial remodelling and airway inflammation were investigated in a mouse model.</p></sec><sec><st>Results</st><p>The different HDM extracts varied extensively in their biochemical properties and induced divergent responses in vitro and in vivo. Importantly, the Greer extract, with the lowest serine protease activity, induced the most pronounced effects on epithelial barrier function and CCL20 release in vitro. In vivo, this extract induced the most profound epithelial E-cadherin delocalisation and increase in CCL20, CCL17 and interleukin 5 levels, accompanied by the most pronounced induction of HDM-specific IgE, goblet cell hyperplasia, eosinophilic inflammation and airway hyper-reactivity.</p></sec><sec><st>Conclusions</st><p>This study shows the ability of HDM extracts to alter epithelial immune and barrier responses is related to allergic sensitisation but independent of serine/cysteine protease activity.</p></sec>]]></description>
<dc:creator><![CDATA[Post, S., Nawijn, M. C., Hackett, T. L., Baranowska, M., Gras, R., van Oosterhout, A. J. M., Heijink, I. H.]]></dc:creator>
<dc:date>2011-12-13T09:44:02-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200606</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200606</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Inflammation, Asthma]]></dc:subject>
<dc:title><![CDATA[The composition of house dust mite is critical for mucosal barrier dysfunction and allergic sensitisation]]></dc:title>
<prism:publicationDate>2011-12-13</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200859v1?rss=1">
<title><![CDATA[A cloudy pleural effusion]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200859v1?rss=1</link>
<description><![CDATA[<sec><st>Case presentation</st><p>A 55-year-old previously fit and well woman was admitted with a 4-week history of dry cough and 1-week history of progressive breathlessness. She had never smoked, was on no regular medications and there was no history of heart disease, malignancy, rheumatological disease or tuberculosis.</p><p>Physical examination revealed signs of a moderate right-sided pleural effusion but was otherwise unremarkable. Full blood count, clotting, and renal and liver function tests were normal. C reactive protein was &lt;5&nbsp;mg/l. Chest x-ray revealed a moderate right sided pleural effusion.</p><p>She underwent bedside diagnostic aspiration of 50&nbsp;ml of pleural fluid which macroscopically appeared cloudy (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). The sample was centrifuged (<cross-ref type="fig" refid="fig1">figure 1B</cross-ref>) and subsequently 10&nbsp;ml of ethyl ether was added (<cross-ref type="fig" refid="fig1">figure 1C</cross-ref>). Results of pleural fluid biochemistry were as follows: protein 68&nbsp;g/l, l<I>actate dehydrogenase</I> 2030&nbsp;IU/l, glucose 1.8&nbsp;mmol/l, pleural fluid cholesterol was 11.2&nbsp;mmol/l (normal range 3.5&ndash;6.5&nbsp;mmol/l) while triglyceride level was 1.8&nbsp;mmol/l (normal...]]></description>
<dc:creator><![CDATA[Malhotra, P., Watson, J. P., Plant, P. K., Bishop, R.]]></dc:creator>
<dc:date>2011-12-13T09:44:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200859</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200859</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[TB and other respiratory infections, Inflammation, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[A cloudy pleural effusion]]></dc:title>
<prism:publicationDate>2011-12-13</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201372v1?rss=1">
<title><![CDATA[Exhale airway bypass stents for emphysema]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201372v1?rss=1</link>
<description><![CDATA[<p>Existing treatment options for severe homogenous emphysema are limited, with dynamic airways collapse and gas trapping minimising the benefits of drug therapy. There has been interest in therapies that address these features more directly. The bronchoscopic lung volume reduction with Exhale airway stents for emphysema trial study group recently reported their findings in <I>The Lancet</I>. The group undertook a multicentre, double-blind, randomised, sham-controlled trial at 38 specialist respiratory centres worldwide. Three hundred and fifteen patients with severe homogenous emphysema were randomised to have sham bronchoscopy (n=107), or up to six Exhale paclitaxel-eluting stents implanted bronchoscopically (n=212). These stents create artificial airways connecting central airways with the emphysematous lung parenchyma and serve as conduits which allow trapped gas to escape thereby reducing both static and dynamic hyperinflation. Unlike lung volume reduction surgery or lung volume reduction using endobronchial valves, this approach does not involve loss of functioning lung tissue by resection...]]></description>
<dc:creator><![CDATA[Zoumot, Z.]]></dc:creator>
<dc:date>2011-12-06T15:56:28-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201372</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201372</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Exhale airway bypass stents for emphysema]]></dc:title>
<prism:publicationDate>2011-12-06</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201078v1?rss=1">
<title><![CDATA[The pneumonectomy syndrome]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201078v1?rss=1</link>
<description><![CDATA[<p>A 47-year-old woman presented with exertional dyspnoea, cough, nausea and weight loss 2&nbsp;years after a right pneumonectomy for non-small cell lung cancer. CT demonstrated marked mediastinal shift and herniation of the left lung into the pneumonectomy cavity (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>). The left lower lobe bronchus was compressed between the aorta and left pulmonary artery and the oesophagus traversed a tortuous path through the right hemithorax (<cross-ref type="fig" refid="fig1">figure 1B</cross-ref>). Respiratory function testing demonstrated gas trapping (residual volume/total lung capacity (RV/TLC) 51%). Surgical intervention to correct the anatomical abnormalities was considered although the patient preferred ongoing conservative management due to perceived risks.</p><p>Pneumonectomy syndrome is a rare complication occurring after pneumonectomy, which was originally described in 1979.<cross-ref type="bib" refid="b1">1</cross-ref> It is reported to occur more frequently in children, presumably due to increased tissue elasticity.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> Careful post-operative management of the pneumonectomy space may play a role in...]]></description>
<dc:creator><![CDATA[Hannan, L. M., Joosten, S. A., Steinfort, D. P., Antippa, P., Irving, L. B.]]></dc:creator>
<dc:date>2011-12-05T07:28:30-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201078</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201078</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Images in Thorax, Journalology, Lung neoplasms, Lung cancer (oncology), Airway biology, Lung cancer (respiratory medicine), Lung function, Cardiothoracic surgery, Ear, nose and throat/otolaryngology, Ethics]]></dc:subject>
<dc:title><![CDATA[The pneumonectomy syndrome]]></dc:title>
<prism:publicationDate>2011-12-05</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200508v1?rss=1">
<title><![CDATA[uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200508v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>The asthma-associated gene urokinase plasminogen activator receptor (uPAR) may be involved in epithelial repair and airway remodelling. These processes are not adequately targeted by existing asthma therapies. A fuller understanding of the pathways involved in remodelling may lead to development of new therapeutic opportunities. uPAR expression in the lung epithelium of normal subjects and patients with asthma was investigated and the contribution of uPAR to epithelial wound repair in vitro was studied using primary bronchial epithelial cells (NHBECs).</p></sec><sec><st>Methods</st><p>Bronchial biopsy sections from normal subjects and patients with asthma were immunostained for uPAR. NHBECs were used in a scratch wound model to investigate the contribution of the plasminogen pathway to repair. The pathway was targeted via blocking of the interaction between urokinase plasminogen activator (uPA) and uPAR and overexpression of uPAR. The rate of wound closure and activation of intracellular signalling pathways and matrix metalloproteinases (MMPs) were measured.</p></sec><sec><st>Results</st><p>uPAR expression was significantly increased in the bronchial epithelium of patients with asthma compared with controls. uPAR expression was increased during wound repair in monolayer and air-liquid interface-differentiated NHBEC models. Blocking the uPA&ndash;uPAR interaction led to attenuated wound repair via changes in Erk1/2, Akt and p38MAPK signalling. Cells engineered to have raised levels of uPAR showed attenuated repair via sequestration of uPA by soluble uPAR.</p></sec><sec><st>Conclusions</st><p>The uPAR pathway is required for efficient epithelial wound repair. Increased uPAR expression, as seen in the bronchial epithelium of patients with asthma, leads to attenuated wound repair which may contribute to the development and progression of airway remodelling in asthma. This pathway may therefore represent a potential novel therapeutic target for the treatment of asthma.</p></sec>]]></description>
<dc:creator><![CDATA[Stewart, C. E., Nijmeh, H. S., Brightling, C. E., Sayers, I.]]></dc:creator>
<dc:date>2011-12-03T00:27:06-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200508</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200508</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Unlocked, Asthma]]></dc:subject>
<dc:title><![CDATA[uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium]]></dc:title>
<prism:publicationDate>2011-12-03</prism:publicationDate>
<prism:section>Asthma</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201329v1?rss=1">
<title><![CDATA[Lebrikizumab may benefit a subset of patients with asthma]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201329v1?rss=1</link>
<description><![CDATA[<p>Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling.</p><p>In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that binds to IL-13 thereby inhibiting its function, was used to investigate the effect on patients with uncontrolled asthma undergoing treatment with inhaled steroids. Lebrikizumab showed superior primary outcome to placebo, with an increase in pre-bronchodilator forced expiratory volume in one second (FEV<SUB>1</SUB>) by 5.5% at week 12. Patients with higher periostin levels had a relative increase in FEV<SUB>1</SUB> of 8.2% compared with those receiving placebo, whereas the low periostin group had a relative increase in FEV<SUB>1</SUB> of 1.6% over the placebo group. There was no significant improvement in secondary outcomes including rates of asthma exacerbation, asthma symptom scores or...]]></description>
<dc:creator><![CDATA[Sithamparanathan, S.]]></dc:creator>
<dc:date>2011-11-25T15:41:44-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201329</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201329</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Lebrikizumab may benefit a subset of patients with asthma]]></dc:title>
<prism:publicationDate>2011-11-25</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201097v1?rss=1">
<title><![CDATA[All that wheezes is not asthma: the value of curves]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201097v1?rss=1</link>
<description><![CDATA[<sec><st>Clinical presentation</st><p>A 64-year-old woman, never smoker, with a history of fully treated tuberculosis at 20&nbsp;years of age attended our department for lung function testing. She had recently experienced several episodes of intermittent breathlessness and wheeze presumed to be due to asthma and was referred to a respiratory physician following an emergency department visit during one of these episodes. She did not have any recent weight loss, night sweats, purulent sputum or haemoptysis. Her dyspnoea and wheeze (inspiratory and expiratory) had been refractory to inhaled corticosteroids and both short and long acting &beta;<SUB>2</SUB> agonists.</p><p>Lung function using American Thoracic Society criteria<cross-ref type="bib" refid="b1">1</cross-ref> (Sensormedics, Yorba Linda, California, USA) showed mild air flow obstruction with forced expiratory volume in one second (FEV<SUB>1</SUB>) of 1.67 l (82% predicted), forced vital capacity (FVC) of 2.92 l (120% predicted) and a FEV<SUB>1</SUB>/FVC ratio of 57%. Total lung capacity was normal (110% predicted). Her maximum flow-volume curves had a...]]></description>
<dc:creator><![CDATA[Seccombe, L. M., Polley, L., Rogers, P. G., Ing, A. J.]]></dc:creator>
<dc:date>2011-11-23T14:53:45-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201097</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201097</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Emergency medicine, Hemoptysis, Airway biology, Asthma, Drugs: respiratory system, Lung function, Cardiothoracic surgery, Transplantation, Health education, Smoking, Tobacco use]]></dc:subject>
<dc:title><![CDATA[All that wheezes is not asthma: the value of curves]]></dc:title>
<prism:publicationDate>2011-11-23</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201059v1?rss=1">
<title><![CDATA[Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201059v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Bone-marrow derived mesenchymal stem cells (MSCs) reduce the severity of evolving acute lung injury (ALI), but their ability to repair the injured lung is not clear. A study was undertaken to determine the potential for MSCs to enhance repair after ventilator-induced lung injury (VILI) and elucidate the mechanisms underlying these effects.</p></sec><sec><st>Methods</st><p>Anaesthetised rats underwent injurious ventilation which produced severe ALI. Following recovery, they were given an intravenous injection of MSCs (2<FONT FACE="arial,helvetica">x</FONT>10<sup>6</sup> cells) or vehicle immediately and a second dose 24&nbsp;h later. The extent of recovery following VILI was assessed after 48&nbsp;h. Subsequent experiments examined the potential for non-stem cells and for the MSC secretome to enhance VILI repair. The contribution of specific MSC-secreted mediators was then examined in a wound healing model.</p></sec><sec><st>Results</st><p>MSC therapy enhanced repair following VILI. MSCs enhanced restoration of systemic oxygenation and lung compliance, reduced total lung water, decreased lung inflammation and histological lung injury and restored lung structure. They attenuated alveolar tumour necrosis factor &alpha; concentrations while increasing concentrations of interleukin 10. These effects were not seen with non-stem cells (ie, rat fibroblasts). MSC-secreted products also enhanced lung repair and attenuated the inflammatory response following VILI. The beneficial effect of the MSC secretome on repair of pulmonary epithelial wounds was attenuated by prior depletion of keratinocyte growth factor.</p></sec><sec><st>Conclusion</st><p>MSC therapy enhances lung repair following VILI via a paracrine mechanism that may be keratinocyte growth factor-dependent.</p></sec>]]></description>
<dc:creator><![CDATA[Curley, G. F., Hayes, M., Ansari, B., Shaw, G., Ryan, A., Barry, F., O'Brien, T., O'Toole, D., Laffey, J. G.]]></dc:creator>
<dc:date>2011-11-21T05:25:57-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201059</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201059</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Adult respiratory distress syndrome, Pneumonia (infectious disease), TB and other respiratory infections, Inflammation, Pneumonia (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat]]></dc:title>
<prism:publicationDate>2011-11-21</prism:publicationDate>
<prism:section>Acute lung injury</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201327v1?rss=1">
<title><![CDATA[Mechanisms underlying the increase in mycobacterial infections in cystic fibrosis patients on azithromycin]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201327v1?rss=1</link>
<description><![CDATA[<p>This study investigated the increased incidence of non-tuberculous mycobacterium (NTM) infections in cystic fibrosis (CF) patients on azithromycin. The authors were particularly interested in autophagia, a process whereby intracellular material is isolated into phagosomes and then destroyed by being fused with acid-rich lysosomes. It is disrupted by other macrolides and is crucial for the clearance of intracellular pathogens.</p><p>In vitro macrophages showed decreased degradation of phagosomes when exposed to azithromycin in both healthy controls and CF patients. This was demonstrated to be mainly due to lysosomal pH being raised to levels that inhibited destructive enzymes and also due to impaired phagosome&ndash;lysosome fusion. Further disruption to immune function was caused by inhibition of cytokine release, as evidenced by decreased levels of interferon  (IFN). In vivo effects were verified by infecting mice with resistant strains of <I>Mycobacterium abscessus</I>. Control groups normally cleared the pathogen within 1&nbsp;month whereas mice treated with azithromycin were...]]></description>
<dc:creator><![CDATA[Jones, G.]]></dc:creator>
<dc:date>2011-11-21T05:25:53-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201327</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201327</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mechanisms underlying the increase in mycobacterial infections in cystic fibrosis patients on azithromycin]]></dc:title>
<prism:publicationDate>2011-11-21</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201267v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201267v1?rss=1</link>
<description><![CDATA[<p>We thank Dr Tournoy for his interest in our article on the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of tuberculous intrathoracic lymphadenopathy.<cross-ref type="bib" refid="b1">1</cross-ref></p><p>With regard to the patient selection in our study, we have acknowledged in the Discussion that the characteristics of patients with intrathoracic lymph node tuberculosis not submitted for EBUS-TBNA are unknown. This selection bias is an inherent problem in retrospective cohort studies, as only those patients suitable for EBUS-TBNA are included. Dr Tournoy would like to know the sensitivity of EBUS-TBNA for all cases in which tuberculous lymphadenitis is suspected; however, this is not reliably obtainable from a retrospective study. We have recently completed the recruitment to a prospective trial of EBUS-TBNA in patients with isolated mediastinal lymphadenopathy, which aims to answer this question (ClinicalTrials.gov identifier: NCT00932854).</p><p>We do not agree with Dr Tournoy's assertion that restricting the sample to patients with the...]]></description>
<dc:creator><![CDATA[Navani, N., Kon, O. M., Janes, S. M.]]></dc:creator>
<dc:date>2011-11-16T01:02:31-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201267</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201267</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-11-16</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201149v1?rss=1">
<title><![CDATA[Tuberculosis through the rose tinted spectacles of the EBUS endoscopist: be aware of the bias]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201149v1?rss=1</link>
<description><![CDATA[<p>I read with interest the article on the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in tuberculous intrathoracic lymphadenopathy by Navani <I>et al</I>.<cross-ref type="bib" refid="b1">1</cross-ref></p><p>EBUS-TBNA has been validated for the assessment of mediastinal nodes in lung cancer<cross-ref type="bib" refid="b2">2</cross-ref> and to obtain a diagnosis in (presumed) centrally located lung cancer<cross-ref type="bib" refid="b3">3</cross-ref> or sarcoidosis.<cross-ref type="bib" refid="b4">4</cross-ref> In addition to a recent report,<cross-ref type="bib" refid="b5">5</cross-ref> the study by Navani <I>et al</I> adds to the evidence for the use of EBUS-TBNA in cases of presumed tuberculous lymphadenitis. A sensitivity of 94% is reported, which might be too optimistic.</p><p>First, patients were selected in a peculiar way. The authors reviewed the files of all EBUS endoscopies and retrospectively selected those cases in which tuberculosis was finally found. Unfortunately, there is no information on how the patients were selected <I>beforehand</I>. The reported figure gives an indication of the sensitivity of EBUS in this particular...]]></description>
<dc:creator><![CDATA[Tournoy, K.]]></dc:creator>
<dc:date>2011-11-16T01:02:31-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201149</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201149</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Tuberculosis through the rose tinted spectacles of the EBUS endoscopist: be aware of the bias]]></dc:title>
<prism:publicationDate>2011-11-16</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201328v1?rss=1">
<title><![CDATA[Cytisine improves smoking cessation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201328v1?rss=1</link>
<description><![CDATA[<p>In this single-centre, randomised, double blind, placebo-controlled trial, the efficacy and safety of cytisine as an aid in smoking cessation was compared with placebo. Three hundred and seventy participants were randomly assigned to either the active drug or placebo in an equal ratio for 25&nbsp;days. Participants in both groups received a minimal amount of counselling during the study.</p><p>The primary outcome measure was sustained biochemically-verified smoking abstinence for 12&nbsp;months after the end of treatment. Secondary outcomes were sustained abstinence for the first 6&nbsp;months and point prevalence at 12&nbsp;months. This study found that the rate of sustained 12-month abstinence was 8.4% (31 participants) in the cytisine group compared with 2.4% (9 participants) in the placebo group. The 7-day point prevalence for abstinence at the 12-month follow-up was 13.2% in the cytisine group and 7.3% in the placebo group. The relative difference in smoking cessation between cytisine and placebo was higher than previous...]]></description>
<dc:creator><![CDATA[Osman, W.]]></dc:creator>
<dc:date>2011-11-16T01:02:31-08:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201328</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201328</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Cytisine improves smoking cessation]]></dc:title>
<prism:publicationDate>2011-11-16</prism:publicationDate>
<prism:section>Miscellaneous</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201043v1?rss=1">
<title><![CDATA[Therapeutic advances in non-small cell lung cancer]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-201043v1?rss=1</link>
<description><![CDATA[<p>Despite decades of research, therapeutic advances in non-small cell lung cancer (NSCLC) have progressed at a painstaking slow rate with few improvements in standard surgical resection for early stage disease and chemotherapy or radiotherapy for patients with advanced disease. In the past 18&nbsp;months, however, we seemed to have reached an inflexion point: therapeutic advances that are centred on improvements in the understanding of patient selection, surgery that is undertaken through smaller incisions, identification of candidate mutations accompanied by the development of targeted anticancer treatments with a focus on personalised medicine, improvements to radiotherapy technology, emergence of radiofrequency ablation (RFA), and last but by no means least, the recognition of palliative care as a therapeutic modality in its own right. The contributors to this review are a distinguished international panel of experts who highlight recent advances in each of the major disciplines.</p>]]></description>
<dc:creator><![CDATA[Vallieres, E., Peters, S., Van Houtte, P., Dalal, P., Lim, E.]]></dc:creator>
<dc:date>2011-11-05T07:12:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-201043</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-201043</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Lung cancer (oncology), Hospice, Lung cancer (respiratory medicine)]]></dc:subject>
<dc:title><![CDATA[Therapeutic advances in non-small cell lung cancer]]></dc:title>
<prism:publicationDate>2011-11-05</prism:publicationDate>
<prism:section>Chest clinic</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200980v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200980v1?rss=1</link>
<description><![CDATA[<p>We read with interest the comments of Dr Singh and colleagues.<cross-ref type="bib" refid="b1">1</cross-ref> We note that in the data submitted from their local population they found a lower mortality for patients with high severity community acquired pneumonia (CAP) (CURB65 score 3&ndash;5) than was found in the National cohort.<cross-ref type="bib" refid="b2">2</cross-ref> It is not possible to precisely explain this difference from the available information, but there are a number of likely explanations. The first is sampling error, which will be inevitable when small numbers of cases are submitted from a large number although their local data collected over a longer time period than the British Thoracic Society (BTS) audit suggest that their lower mortality score is real. A differential response to treatment is a consideration, but since only selected aspects of patient care were documented in the audit, this aspect cannot be properly examined. The most likely explanation of all is...]]></description>
<dc:creator><![CDATA[Lim, W. S., Woodhead, M.]]></dc:creator>
<dc:date>2011-09-20T08:41:03-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200980</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200980</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-09-20</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200206v1?rss=1">
<title><![CDATA[Immunity and bacterial colonisation in bronchiectasis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200206v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Non-cystic fibrosis bronchiectasis is characterised by irreversibly dilated bronchi usually associated with chronic sputum production, bacterial colonisation of the lower respiratory tract, inflammation and frequent exacerbations. Irrespective of the underlying cause, this represents failure of the host defence to maintain sterility of the respiratory tract.</p></sec><sec><st>Objective</st><p>To review the interactions and associations of non-cystic fibrosis bronchiectasis with the inate and adaptive immune systems with particular emphasis on known failure of local defences established deficiencies of the adaptive immune system. In addition we wished to explore potential subtle changes in the host defence which can lead to bacterial colonisation together with bacterial factors that aid colonisation of the lower respiratory tract and impair antibiotic response. This latter concept is considered with particular reference to Pseudomonas aeruginosa, which is often found in the airway secretions of patients with non-cystic fibrosis bronchiectasis and may act as a model for other organisms.</p></sec><sec><st>Methods</st><p>An extensive literature review was undertaken to provide a comprehensive review of immunity and bacterial colonisation in non-cystic fibrosis bronchiectasis, with focus on in vitro studies examining bacterial factors which may facilitate colonisation together with potential implications for management.</p></sec><sec><st>Conclusion</st><p>These themes provide a review of the current understanding of non-cystic fibrosis bronchiectasis together with areas for future research and potential therapeutic strategies.</p></sec>]]></description>
<dc:creator><![CDATA[Whitters, D., Stockley, R.]]></dc:creator>
<dc:date>2011-09-20T08:41:03-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200206</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200206</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Immunity and bacterial colonisation in bronchiectasis]]></dc:title>
<prism:publicationDate>2011-09-20</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200876v1?rss=1">
<title><![CDATA[Using the BTS CAP audit to evaluate local data]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200876v1?rss=1</link>
<description><![CDATA[<p>We read Dr Lim and Dr Woodhead's update on the British Thoracic Society (BTS) 2009/2010 community acquired pneumonia (CAP) audit with interest and noted the high inpatient mortality rate of 18.3%.<cross-ref type="bib" refid="b1">1</cross-ref> As a contributing site, we received a useful summary of our data in comparison with the national data and local mortality rates for severe CAP (CURB65 3-5) were 21.4% versus 42.6% nationally. This provoked an examination of local severe CAP admissions between December 2009 and May 2011 (n=169) that found 25% mortality with age, gender and comorbidity distributions similar to national audit data. We suspect variations in case definitions may be important in understanding differences between local and national data.</p><p>The <I>Thorax</I> report focuses on adherence to local antibiotic guidelines. Nationally, 55.5% of patients received antibiotics in line with local prescribing policies (64% in severe CAP), but there was no association between adherence and mortality.<cross-ref type="bib" refid="b1">1</cross-ref> From...]]></description>
<dc:creator><![CDATA[Singh, B., Wootton, D. G., Brown, J., Chakrabarti, B., Cooke, R. P. D., Gordon, S. B., on behalf of the University Hospital Aintree Pneumonia Group]]></dc:creator>
<dc:date>2011-09-20T08:41:02-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200876</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200876</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Using the BTS CAP audit to evaluate local data]]></dc:title>
<prism:publicationDate>2011-09-20</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200822v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200822v1?rss=1</link>
<description><![CDATA[<p>We thank Dr Young for his comments on the recent UKLS position statement.<cross-ref type="bib" refid="b1">1</cross-ref> We are aware of the current studies on chronic obstructive pulmonary disease (COPD) and lung cancer. However, there is no validated lung cancer risk model in the UK which currently incorporates dynamic lung volumes that could be used in the UKLS trial. All the recruited individuals will have spirometry at the time that they are recruited into the UKLS trial, thus data will be available for developing the Liverpool Lung Project risk model.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> We do not wish to focus on COPD risk groups for the pilot UKLS trial.</p><p>Smoking is the over-riding risk factor in lung cancer. Our measurements will provide further information concerning the potential for COPD as a useful factor in selecting populations that may benefit from screening. We do not have population-based spirometry in the UK to screen...]]></description>
<dc:creator><![CDATA[Field, J., Baldwin, D., Brain, K., Devaraj, A., Eisen, T., Duffy, S. W., Hansell, D. M., Kerr, K., Page, R., Parmar, M., Weller, D., Whynes, D., Williamson, P.]]></dc:creator>
<dc:date>2011-09-13T14:24:27-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200822</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200822</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-09-13</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200766v1?rss=1">
<title><![CDATA[CT screening for lung cancer]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200766v1?rss=1</link>
<description><![CDATA[<p>We read with interest the recent opinion piece by Field <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> outlining plans for a CT screening trial in the United Kingdom (the UK Lung Screen (UKLS)) following the results of the National Lung Cancer Screening Trial. We agree that cost-effectiveness and defining who would most likely benefit from CT screening remain key issues to be resolved before CT screening can be offered routinely in clinical practice.<cross-ref type="bib" refid="b2">2</cross-ref></p><p>First, cost-effectiveness is most likely to be achieved through optimising the risk assessment of those potentially eligible for CT screening<cross-ref type="bib" refid="b1">1</cross-ref> and maximising the number of cancers identified for each scan done. While historical data may assist in this risk assessment,<cross-ref type="bib" refid="b2">2</cross-ref> it is possible that biomarkers are required to better stratify this risk. In this regard, we and others have shown that a reduced forced expiratory volume in one second (FEV<SUB>1</SUB>) is the single most important...]]></description>
<dc:creator><![CDATA[Young, R. P., Hopkins, R. J.]]></dc:creator>
<dc:date>2011-09-13T14:24:27-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200766</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200766</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[CT screening for lung cancer]]></dc:title>
<prism:publicationDate>2011-09-13</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200762v1?rss=1">
<title><![CDATA[CT screening for lung cancer: so near, yet so far]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200762v1?rss=1</link>
<description><![CDATA[<p>The UK Lung Screen team in their positional statement outlined the issues to be explored by the trial on CT screening for lung cancer.<cross-ref type="bib" refid="b1">1</cross-ref> Although it seems to be a large, well-planned study, we believe that there are some shortcomings in this study that may undermine its significance. There are several other aspects of CT screening that need to be investigated in order to determine the suitability of the screening and thus guide a national programme. The additional investigation areas may include:</p><p><l type="ord"><li><p>Studying the number of unnecessary lung biopsies, invasive procedures and surgeries due to cancer screening and the morbidity and mortality caused by these procedures.</p></li><li><p>The risk of development of radiation-induced malignancy, both in patients undergoing routine yearly screening and in those subjected to serial CT scans for suspicious lesions. Some studies have shown significant risk of development of radiation-induced malignancies.<cross-ref type="bib" refid="b2">2</cross-ref></p></li><li><p>Smoking abstinence behaviour in people undergoing...]]></description>
<dc:creator><![CDATA[Dutt, N., Hari, D. T.]]></dc:creator>
<dc:date>2011-09-13T14:24:27-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200762</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200762</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[CT screening for lung cancer: so near, yet so far]]></dc:title>
<prism:publicationDate>2011-09-13</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200695v1?rss=1">
<title><![CDATA[Progressive static pulmonary hyperinflation in survivors of severe bronchopulmonary dysplasia by mid-adulthood]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200695v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Severe bronchopulmonary dysplasia (BPD) might be associated with an accelerated age&ndash;related decline of lung function.</p></sec><sec><st>Methods</st><p>14 individuals were studied longitudinally at 15&plusmn;4, 18&plusmn;3 and 38&plusmn;3.2 years. Information on personal history was completed, and lung function testing and skin prick testing were performed. Longitudinal data were compared intra-individually and with matched controls from the NHANES III dataset.</p></sec><sec><st>Results</st><p>The ratio of residual volume/total lung capacity (RV/TLC) increased markedly from 25.9&plusmn;7.0% to 39.3&plusmn;6.8%. A significant time-effect was found compared to controls for the forced vital capacity (FVC) which decreased more rapidly than expected. Flow values were at the lower limit of normal range but remained relatively stable over time. Some individuals had completely normal lung function results.</p></sec><sec><st>Conclusion</st><p>Increasing static pulmonary hyperinflation with age is indicative of bronchiolar dysfunction or early emphysematous changes in survivors of severe BPD. Susceptibility for long-term sequelae shows significant variability.</p></sec>]]></description>
<dc:creator><![CDATA[Trachsel, D., Brutsche, M. H., Hug-Batschelet, H., Hammer, J.]]></dc:creator>
<dc:date>2011-08-25T22:36:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200695</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200695</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Progressive static pulmonary hyperinflation in survivors of severe bronchopulmonary dysplasia by mid-adulthood]]></dc:title>
<prism:publicationDate>2011-08-25</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200657v1?rss=1">
<title><![CDATA[Pragmatic trials: how to adjust for the 'Hawthorne effect'?]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200657v1?rss=1</link>
<description><![CDATA[ <p>Hashimoto <I>et al</I><cross-ref type="bib" refid="b1">1</cross-ref> have conducted an interesting study to offer a practical and pragmatic insight into steroid-dependent asthma therapeutics in real-world practice. They proposed a strategy based on internet monitoring of objective (spirometry and fraction of exhaled nitric oxide) and subjective (asthma control and asthma-related quality of life questionnaires) measurements to adjust the dose of oral corticosteroids in patients with severe, uncontrolled asthma. However, how &lsquo;pragmatic&rsquo; is a trial in which the patients have to sign an informed consent in order to participate in the study? Signing informed consents or receiving simple verbal instructions has been shown to significantly influence the outcome of interest in simple or more complicated studies.<cross-ref type="bib" refid="b2">2</cross-ref> <cross-ref type="bib" refid="b3">3</cross-ref> This is known as the &lsquo;Hawthorne effect&rsquo; or the unexpected and unexplained reactivity to experimentation in human subjects who are aware of their participation in a study.<cross-ref type="bib" refid="b4">4</cross-ref> Specifically in asthma,...]]></description>
<dc:creator><![CDATA[Konstantinou, G. N.]]></dc:creator>
<dc:date>2011-08-23T21:26:41-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200657</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200657</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Pragmatic trials: how to adjust for the 'Hawthorne effect'?]]></dc:title>
<prism:publicationDate>2011-08-23</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200870v1?rss=1">
<title><![CDATA[Authors' response]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200870v1?rss=1</link>
<description><![CDATA[ <p>We thank Dr Konstantinou for his interesting letter<cross-ref type="bib" refid="b1">1</cross-ref> in response to our paper on internet-based management of severe asthma.<cross-ref type="bib" refid="b2">2</cross-ref> He raises a pertinent question about how pragmatic is a study in which the patients have to give their consent to participate? We agree that asking patients to sign for their participation takes the study a step away from real-life settings, but it would be unethical to perform an interventional study without obtaining the patient's permission for randomisation and data to be collected. There are alternative approaches, proposed by Zelen in 1979,<cross-ref type="bib" refid="b3">3</cross-ref> and mainly used in emergency settings, consisting of post-randomisation consent. In such designs, it is allowed for participants to refuse their allocated treatment or &lsquo;crossover&rsquo; to any treatment arm. However, this method is ethically very controversial and could result in some serious statistical drawbacks.<cross-ref type="bib" refid="b4">4</cross-ref></p> <p>Another point mentioned by Dr Konstantinou...]]></description>
<dc:creator><![CDATA[Hashimoto, S., Sterk, P. J., Bel, E. H.]]></dc:creator>
<dc:date>2011-08-23T21:26:41-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200870</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200870</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Authors' response]]></dc:title>
<prism:publicationDate>2011-08-23</prism:publicationDate>
<prism:section>PostScript</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200662v2?rss=1">
<title><![CDATA[Pulmonary hypertension and lung transplantation: Thorax publication activity review 2008-2010]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200662v2?rss=1</link>
<description><![CDATA[
<p>A review is presented on articles published in <I>Thorax</I> between 2008 and 2010 relating to lung transplantation and pulmonary hypertension.</p>
]]></description>
<dc:creator><![CDATA[Haja Mydin, H., Fisher, A. J.]]></dc:creator>
<dc:date>2011-07-18T16:17:05-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200662</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200662</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Pulmonary hypertension and lung transplantation: Thorax publication activity review 2008-2010]]></dc:title>
<prism:publicationDate>2011-07-18</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200515v1?rss=1">
<title><![CDATA[Idiopathic pulmonary fibrosis]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200515v1?rss=1</link>
<description><![CDATA[
<p>Idiopathic pulmonary fibrosis is a progressive lung disease that carries a poor prognosis and for which there are no effective therapies. Although the excessive deposition of extracellular matrix, combined with evidence of recurrent injury to the alveolar epithelium, are well-described there is a pressing need to understand these processes better at a molecular level and thus to identify potential therapeutic targets in this intractable disease. This review considers some recent advances published in <I>Thorax</I> and elsewhere that have improved our understanding of the pathophysiology of idiopathic pulmonary fibrosis, using data both from human cells and tissue and from animal models of pulmonary fibrosis. The studies particularly address the fate of the alveolar epithelial cell and mechanisms of fibrogenesis, and identify mechanistic pathways shared with co-existing conditions such as lung cancer and pulmonary hypertension. The concepts of physiological biomarkers of disease progression and prognosis are also discussed.</p>
]]></description>
<dc:creator><![CDATA[Hoo, Z. H., Whyte, M. K. B.]]></dc:creator>
<dc:date>2011-06-22T08:05:54-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200515</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200515</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Idiopathic pulmonary fibrosis]]></dc:title>
<prism:publicationDate>2011-06-22</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200467v1?rss=1">
<title><![CDATA[Cystic fibrosis, primary ciliary dyskinesia and non-cystic fibrosis bronchiectasis: update 2008-11]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200467v1?rss=1</link>
<description><![CDATA[
<p>A review is presented of key clinical papers published in <I>Thorax</I> and elsewhere between 2008 and April 2011 which have advanced our understanding of cystic fibrosis (CF), primary ciliary dyskinesia and non-CF bronchiectasis. Studies were identified through searches of the <I>Thorax</I> archive and the Medline database. Within the field of CF, the following key themes were studied: diagnosis in equivocal CF, assessment of CF lung disease, novel therapies addressing the basic defect in CF, maintenance pulmonary therapies, management of early <I>Pseudomonas</I> infection, the microbiology of CF lung disease, renal impairment in CF and controversies in lung transplantation in CF.</p>
]]></description>
<dc:creator><![CDATA[Flight, W. G., Jones, A. M.]]></dc:creator>
<dc:date>2011-06-15T23:58:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200467</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200467</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Cystic fibrosis, primary ciliary dyskinesia and non-cystic fibrosis bronchiectasis: update 2008-11]]></dc:title>
<prism:publicationDate>2011-06-15</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200088v1?rss=1">
<title><![CDATA[Mechanisms of neutrophil transmigration across the vascular endothelium in COPD]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thoraxjnl-2011-200088v1?rss=1</link>
<description><![CDATA[
<p>Chronic obstructive pulmonary disease (COPD) is a common and important disease. Neutrophils have been shown to play a fundamental role in its development and progression. Understanding the mechanisms underlying the trafficking of neutrophils across the vascular endothelium into the lung could potentially allow the development of targeted biological treatments. The early stages of neutrophil tethering, adherence to and rolling on the endothelium have been determined. The later stages of diapedesis through the glycocalyx, endothelial cell (EC) layer and basement membrane, which are less well characterised, have been reviewed here. Evidence obtained from in vitro and in vivo work, concerning the implicated adhesion molecules on the neutrophil and endothelium, the mechanisms for neutrophil navigation through the EC junction (paracellular route) and evidence for transmigration through the body of an EC itself (transcellular route), is considered. The mechanisms are complex and are often disease and stimulus specific. There is evidence that a significant degree of redundancy occurs. Transmigration in the lung differs from that in other organs in that the neutrophil can exit the circulation either through the postcapillary venule in the systemic circulation or through the capillary in the pulmonary circulation. A number of factors make the mechanisms of transmigration within the lung and COPD model unique. These include physical differences between the flow through the capillary and the postcapillary venule, the modulating effect of the alveolar epithelium and other cells such as the macrophage, the presence of a &lsquo;diseased&rsquo; neutrophil and indeed the presence or absence of acute, acute on chronic or chronic pulmonary disease.</p>
]]></description>
<dc:creator><![CDATA[Gane, J., Stockley, R.]]></dc:creator>
<dc:date>2011-05-04T05:25:47-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thoraxjnl-2011-200088</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thoraxjnl-2011-200088</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Mechanisms of neutrophil transmigration across the vascular endothelium in COPD]]></dc:title>
<prism:publicationDate>2011-05-04</prism:publicationDate>
<prism:section>Reviews</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thx.2010.142653v1?rss=1">
<title><![CDATA[Proposal for a systematic analysis of polygraphy or polysomnography for identifying and scoring abnormal events occurring during non-invasive ventilation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thx.2010.142653v1?rss=1</link>
<description><![CDATA[
<p>Non-invasive ventilation (NIV) is recognised as an effective treatment for chronic hypercapnic respiratory failure. Monitoring NIV during sleep may be preferable to daytime assessment. This paper reports the findings of an international consensus group which systematically analysed nocturnal polygraphic or polysomnographic tracings recorded with either volume-cycled or pressure-cycled ventilators. A systematic description of nocturnal respiratory events which occur during NIV is proposed: leaks, obstruction at different levels of the upper airway (glottis and/or pharynx), with or without decrease of respiratory drive and asynchrony.</p>
]]></description>
<dc:creator><![CDATA[Gonzalez-Bermejo, J., Perrin, C., Janssens, J. P., Pepin, J. L., Mroue, G., Leger, P., Langevin, B., Rouault, S., Rabec, C., Rodenstein, D., on behalf of the SomnoNIV Group]]></dc:creator>
<dc:date>2010-10-22T22:45:29-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thx.2010.142653</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thx.2010.142653</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Proposal for a systematic analysis of polygraphy or polysomnography for identifying and scoring abnormal events occurring during non-invasive ventilation]]></dc:title>
<prism:publicationDate>2010-10-22</prism:publicationDate>
<prism:section>Review series</prism:section>
</item>
<item rdf:about="http://thorax.bmj.com/cgi/content/short/thx.2009.133496v1?rss=1">
<title><![CDATA[Wegener granulomatosis with a large area of consolidation]]></title>
<link>http://thorax.bmj.com/cgi/content/short/thx.2009.133496v1?rss=1</link>
<description><![CDATA[ <p>A 51-year-old woman was admitted to our hospital with general fatigue, fever and cough. Upon examination, sinusitis, papules of the planta, polymorph leucocytosis, hypoalbuminaemia and an elevated level of PR3-antineutrophil cytoplasmic antibodies (ANCAs) were found. Her chest radiograph (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>) and thoracic CT (<cross-ref type="fig" refid="fig1">figures 1B</cross-ref> <cross-ref type="fig" refid="fig2">2A</cross-ref>) demonstrated a large area of consolidation with air bronchogram and cavitation in the right lung field. Specimens of biopsy from skin, lung and kidney showed necrotising granulomatous vasculitis. The patient was given a diagnosis of Wegener granulomatosis (WG) and treated with corticosteroid and cyclophosphamide. The consolidation resolved with residual scarring and was transformed into cystic lesions (<cross-ref type="fig" refid="fig2">figure 2B</cross-ref>).</p> <p>The lung is the most commonly involved organ in WG, and the most representative CT findings are multiple nodules, occasionally with cavitation. Areas of consolidation and ground-glass attenuation are also frequent findings, which represent granulomatous changes and...]]></description>
<dc:creator><![CDATA[Takimoto, T., Morimura, O., Inoue, T., Terada, H., Abe, K.]]></dc:creator>
<dc:date>2010-07-29T17:29:46-07:00</dc:date>
<dc:identifier>info:doi/10.1136/thx.2009.133496</dc:identifier>
<dc:identifier>hwp:master-id:thoraxjnl;thx.2009.133496</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Wegener granulomatosis with a large area of consolidation]]></dc:title>
<prism:publicationDate>2010-07-29</prism:publicationDate>
<prism:section>Images in Thorax</prism:section>
</item>
</rdf:RDF>
